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ABSTRACT 
Insulin promotes vasodilatory, vasoconstrictor and atherogenic influences on 
vascular smooth muscle. Endothelin- 1 (ET- 1) is a potent, endothelium derived 
vasoconstrictor1mitogenic peptide whose production is stimulated by insulin both in 
vitro and in vivo. Consequently, ET-1 has been hypothesized to contribute to insulin 
evoked vasculopathy. The present study first characterized the effect of insulin and 
the insulinomimetic agent, vanadate, on ET receptor expression and action in rat 
aortic smooth muscle cells. Radioligand binding studies confirmed that insulin 
pretreatment selectively upregulated ETA receptor expression in a concentration and 
time dependent manner, whereas vanadate upregulated both ETA and ETB. 
Upregulated ET receptors were coupled to increased [CaZfli. Upregulation by both 
compounds occurred at the mRNA level and required tyrosine kinase activation, 
active transcription, and new protein synthesis. In order to determine the in vivo 
relevance of these effects, both insulin deficient diabetic and non-diabetic rats were 
treated with insulin and vanadate for 2-weeks. Strikingly, the diabetic state per se 
was associated with both attenuated ET-1 plasma levels and exaggerated ex vivo 
aortic vasoconstrictor responses to ET-1. Two weeks of treatment with either insulin 
or vanadate did not further increase ET-1 evoked vasoconstriction as expected based 
on our cellular data, but in fact restored altered ET-1 release and action to normal in 
the diabetic rats. It is concluded that while insulin and vanadate might increase ET 
receptor expression and subsequent adverse vascular responses to ET-1, their 
profound beneficial effects on metabolic function and the resulting beneficial 
vascular actions clearly minimize the significance of these actions. 
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INSULINOMIMETICS AND THE VASCULAR 
ENDOTHELIN SYSTEM 
1. INTRODUCTION 
1.1. Endothelins 
1 . 1 1  Discovery of a novel endothelium derived contracting factor (EDCF) 
It was just 20 years ago that Furchgott and Zawadzki made the serendipitous, yet 
seminal discovery that the vascular endothelium mediates vascular relaxation by 
releasing a substance in response to stimulation with acetylcholine (ACh; Furchgon 
& Zawadzki, 1980). This substance was shown to be non-prostanoid in nature and 
was later identified as the gas, nitric oxide (Ignarro et al., 1987). Around the same 
time, endothelial cell (EC) cultures were also shown to produce a peptide that 
contracted both bovine pulmonary arteries (0 'Brien and McMurtry , 1 987), and 
isolated coronary arteries (Hickey et al., 1985). This substance was soon after 
characterized in the conditioned culture medium of porcine aortic EC and was 
determined to be the most potent and long-lasting vasoconstrictor agonist known to 
man (Yanagisawa et al. 1 988). The substance was named endothelin- l (ET- I ). 
1.1.2. Structural biology of endothelin-l and i ts  isoforms 
ET-1 was determined to have a molecular weight of 2492 and contain 21 amino 
acids, with free amino and carboxy termini and two intrachain disulfide bonds. The 
human genome contains coding regions for two other structurally distinct endothelin 
(ET) isopeptides, ET-2 and ET-3 (Inoue et al., 1989). Each of these isoforms exhibit 
a high degree of sequence homology but different pharmacological profiles 
(D'Orleans-Juste et al., 1991a). The primary structure of ET-2 differs fiom ET-1 
with respect to 2 amino acid residues, whereas ET-3 differs with respect to 6 (Figure 
1). ET's are bicyclic peptides with a hairpin loop configuration with two disulphide 
bonds interlinked between Cysl and Cys 15 and Cys 3 and Cys I1  (Rubanyi & 
Polokoff, 1994). The 3-D structure of ET-1 is presented in Figure 2. It is notable 
that both the hydrophobic C-terminus and hairpin-loop codiguration is required for 
biological activity (Kimura et al. 1988). 
1.1.3. Regulation of  endothelin- 1 production 
Synthesis of ET-1 occurs in various tissues including EC (Yanagisawa et al. 1988), 
vascular smooth muscle cells (VSMC; Resink et al. 1990a), bronchial epithelial cells 
(Black et al. 1989), mesangial ceHs (Kohno et al., 1992), cardiac myocytes (Suzuki 
et al. 1993), and glial cells. EC produce almost exclusively ET-1 (Inoue et al., 
1989). A pictorial of the synthetic pathway of ET production is represented in 
Figure 3. Sequence analysis of porcine ET-1 cDNA revealed the existence of a 
single copy gene encoding a precursor protein, preproET-1. This 203 amino acid 
precursor, formed upon translation of mRNA specific for ET-1, is acted upon by a 
dibasic-pair specific endopeptidase to form the 38-39 amino acid peptide, big-ET-1. 
big ET-1 is then acted upon by the protease, ET converting enzyme (ECE) found 
both within the cell of synthesis (in the golgi complex) and on the membrane of 
target cells. ECE cleaves the Trp-2 1-Val-22 bond to yield biologically active ET- 1. 
The secretion of ET-1 is thought to occur immediately after its formation as there are 
no reports of storage granules for the peptide. ET gene transcription can be 
enhanced by various factors including angiotensin I1 (Ang 11), insulin, thrombin, 
platelet derived growth factor, arginine vasopressin (AVP), transforming growth 
factor+, phorbol ester, oxidized low-density lipoprotein (LDL), hypoxia, and shear 
stress (Miyauchi & Masaki, 1999). Inhibitory stimuli can also modulate ET-1 
production including endothelium derived relaxing factor (EDRF), atrial natriuretic 
factor, cyclic GMP, nitrosovasodilators, prostacyclin (PGI*), and heparin. 
Accordingly, pathophysiological conditions whereby impaired formation of EDRF 
and/or PG12 is present may be associated with enhanced ET- 1 synthesis. 
1.1.4. Characteristics and function of endothelin receptors 
To date, there have been two ET receptor subtypes sequenced and cloned, ETA and 
ETB. The IUPHAR Committee on Nomenclature and Drug Classification identified 
the ETA receptor as having higher affinity for ET-1 than ET-2 compared to ET-3 
and the ETB receptor for having similar affinity for all three isofoms (Masaki et al., 
1994). The human ETA receptor is 427 amino acids and belongs to the seven- 
transmembrane spanning G-protein coupled receptor superfarnily. The ETB receptor 
is a 41 5 amino acid protein also belonging to the G-protein receptor family. There is 
68% conserved amino acid identity between human ETA and ETB receptors. A high 
density of binding sites for ET-1 have been demonstrated in many tissues of the 
body including brain, blood vessels, heart, kidney, lungs, gastro-intestinal tract, 
spleen, liver, adrenal gland, and eye. Those tissues expressing predominantly ETA 
include VSMC, human heart, and pituitary gland. Those expressing predominantly 
ETB include EC's, renal cortex, brain, and lungs. Radioligand binding studies 
indicate that ['**I] ET-1 binding is specific, saturable, and of high affi~nity. KD and 
B,, values reported range from 0.01 - 1.0 nM and 0.1 to 1.0 pmoVmg protein, 
respectively. One unique aspect of ET-1 binding is its extremely slow dissociation 
fiom its receptor. This is the proposed reason for its long lasting, persisting 
vasoconstrictor effect. The ETA receptor is accepted to be the main subtype 
modulating contractile and mitogenic responses in vascular, cardiac, lung, and renal 
tissues. It is also thought to modulate other functions such as stimulation of 
lipoprotein lipase activity in adipocytes, regulate urinary bladder tone, and 
participate in central cardiovascular regulation. The ETB receptor expressed on 
EC's is involved in the regulation of EDRF and PG12, which results in a transient 
vasodilator and anti-aggregatory response in platelets (D'Orleans-Juste et al., 
199 1 b). However, similar to the ETA receptor, the ETB receptor located on smooth 
muscle cells is coupled to contractile and mitogenic responses. Such tissues where 
this may be physiologically relevant include the pulmonary artery, bronchial smooth 
muscle, and kidney, coronary, and venous circulation. The contributions of ETA and 
ETB receptors to these responses are, however, widely species dependent. Other 
functions of the ETB receptor include modulation of renal tubular ion transport, 
receptor mediated clearance of ET-1, and anti-aggregatory responses in platelets. 
1.1 .5. Physiological actions of endothelin-1 
1.1.5.1. Autocrine, paracrine, and endocrine role 
Another unique function of the ET system is its ability to act in an endocrine, 
paracrine, and autocrine manner (Rubanyi & Polokoff, 1994). By way of its 
autocrine effects, ET-1 elaborated fiom the vascular endothelium stimulates its own 
receptors (ETB) on EC promoting the release of PGIz and EDRF. Perhaps more 
importantly, ET-1 released fiom EC may act in a paracrine manner on underlying 
VSMC to promote contraction and mitogenesis. While ET- 1 was initially 
considered a local hormone based on such autocrine and paracrine functions and 
because of the fact that it is rapidly cleared from the plasma via the lung and 
kidneys, some evidence supports the view that it may also act in an endocrine 
manner. In this regard, ET-1 has been shown to act as a glycogenolytic (Jouneaux et 
al., 1993), modulate the release of catecholamines fiom the adrenal medulla and 
sympathetic nervous system (Boarder & Marrit, 199 1 ), and stimulate the pituitary to 
release follicle stimulating hormone and leutenizing hormone (Stojilkovic et al., 
1992). 
1.1.5.2. Signal transduction 
Binding of ET- 1 to its cell-surface receptors stimulates complex pathways of signal 
transduction resulting in characteristic short and long-term effects (Figure 4; 
Rubanyi & Polokoff, 1994) that mediate its profound vasoconstrictor effect in VSM. 
Binding of ET-1 to either ETA or ETB receptors results in coupling to phospholipase 
C (PLC) by both pertussis toxin sensitive and insensitive G-proteins. A rapid 
increase in inositol-trisphosphate (IP3) levels results, which subsequently stimulates 
increased release of ~ a 2 +  fiom the sarcoplasmic reticulum (SR) followed by a 
prolonged influx of extracellular Ca2+ through L-type channels. In the absence of 
extracellular caZC, the sustained increase in [CaZf ] is abolished (Simonson et al., 
1992). While the initial report by Yanagisawa et al. (1988) suggested that ET-1 
directly interacts with dihydropyridine sensitive ~ a * +  channels, subsequent reports 
indicate that ET-1 mediated activation of L-type channels occurs through diffusible 
second messengers (Rubanyi & Polokoff, 1994). The other second messenger 
liberated by PLC activation is diacylglycerol (DAG) which, along with Ca*+ and 
phosphatidylserine, activates protein kinase C (PKC). PKC regulates a variety of 
intracellular functions through phosphorylation of proteins (Nishiruka, 1988). ET- 1 
mediated vasoconstriction has been shown to occur even in the absence of changes 
in [Ca*+Ii. This response is mediated by activation of "novel" ~ a * +  independent 
isofonns of PKC. PKC activation has also been implicated in the promitogenic 
effect of ET-1. ET-1 also increases the phosphorylation of cellular proteins at 
tyrosine residues probably through activation of mitogen activated protein kinases 
(MAPK) (Wang et al., 1992). ET- 1 also activates phospholipase D (PLD) resulting 
in the production of phosphatidic acid, choline, or ethanolamine fiom membrane 
bound phospholipids such as phosphatidylcholine and phosphatidylethanolamine. 
This occurs through both PKC dependent and direct G-protein mediated mechanisms 
(MacNaulty et al., 1990). ET-1 also activates PLAZ leading to the formation of 
leukotrienes, thromboxanes, and prostaglandins (Resink et al., 1 99Ob). This is 
thought to occur again through both G-protein coupled mechanisms and by increases 
in [Ca2+Ii, and also possibly by parallel but separate pathways (Axelrod et al., 1988, 
Resink et al., 1 99Ob). Finally, the mitogenic properties of ET-1 result fiom an effect 
on the expression of transcription factors such as c-fos, c-jun, and c-myc (Simonson 
et al., 1989). These events are thought to result from stimulation of protein tyrosine 
kinases, such as MAPK (Simonson et al., 1992). 
1.1.5.3. Cardiovascular actions 
ET-1 potently induces vasoconstriction in various vascular beds. ET-1 produces 
contractile responses in VSMC that are characteristically long lasting and difficult to 
wash out (Yanagisawa et al., 1988). This response is mediated by both ETA and 
ETB receptors present on VSMC, the degree to which each subtype contributes 
being dependent on the species and vascular bed under investigation (Gardiner et al., 
1994). Subthreshold concentrations of ET- 1 are also thought to potentiate 
vasoconstrictor responses to other agonists (MacLean and MacGrath, 1990). ET- 1 
also simultaneously promotes vasodilatation through stimulation of endothelial ETB 
receptors and the subsequent release of EDRF. The simultaneous release of EDRF 
not only physiologically antagonizes contraction induced by ETA and ETB 
stimulation on VSMC, but may also promote dissociation of the ET-1-peptide 
receptor complex (Goligonky et al., 1994). These opposing actions of ET-1 no 
doubt contribute to the characteristic biphasic change in arterial blood pressure (BP) 
elicited by the peptide, consisting of a transient depressor response followed rapidly 
by a sustained pressor response (Yanagisawa et al., 1988). In addition to modulating 
peripheral vascular function directly, ET-1 also modulates systemic hernodynamics 
through central mechanisms. Importantly, ET-1 is a basal regulator of 
cardiovascular tone (Haynes et al., 1996). ET-1 also acts as a potent mitogen of 
several cardiovascular cells by enhancing expression of protooncogenes, and 
stimulation of production of other growth factors including platelet derived growth 
factor, epidermal growth factor, transforming growth factor+, fibroblast growth 
factor, insulin, and insulin like growth factor -1 (IGF-I). It may also act as a co- 
mitogen with these factors (Brown & Littlewood, 1989; Frank et al., 1993). ET-1 
also modulates hemostasis by indirectly modulating the in vivo and ex vivo 
aggregratory properties of platelets (Thiemermann et al., 1988). This response is 
mediated by ETB stimulated PGIl and EDRF production that inhibits ADP-induced 
ex vivo plateiet aggregation (de Nucci et. al., 1 988; McMurdo et al., 1993). Through 
such indirect mechanisms, ET-1 also modulates vascular permeability (Filep et al., 
1991). Finally, aside from expected growth and vasoconstrictor actions in the renal 
vasculature, ET-I is also thought to have direct diuretic effects. These effects are 
mediated through inhibition of both AVP induced water transport (Tomita et al., 
1992) and tubular sodium and bicarbonate transport (Perico et al., 1991). While 
most of the cardiovascular actions of ET- 1 can be attributed to the above mentioned 
mechanisms, several other unique actions of ET-1 have been identified in various 
other organ systems of the body including the reproductive system, prostate, 
hypophyseal system, adrenal glands, thyroid, bone, and the gastrointestinal system. 
Figure 1. Primary structures of the three ET isopeptides. ET-2 differs from ET-1 
with respect to 2 amino acid residues, whereas ET-3 differs with respect to 6 
(adapted from Rubanyi & Polokoff, 1994). 
Figure 2. 3-Dimensional structure of  ET-1. ET-1 is a bicyciic, 21 amino acid 
peptide with a hairpin loop configuratipon containing two disulphide bonds 
interlinked between Cysl and Cys 15 and Cys 3 and Cys 1 1 .  Both the hydrophobic 
C-terminus and hairpin-loop configuration is required for biological activity 
(adapted from website: http://www.fmed.ulaval.ca/et6/map-e.htm). 
Figure 3. Pathways of formation of ET-I. Prepro-ET-1, a 203 amino acid 
precursor formed upon translation of mRNA specific for ET-1, is acted upon by a 
dibasic-pair specific endopeptidase to form the 38-39 amino acid peptide big-ET-1. 
big ET- 1 is then acted upon by the protease, ECE that cleaves the Trp-2 1 -Val-22 
bond to yield biologically active ET-1. Secretion of ET-1 is regulated by various 
stimulatory and inhibitory factors and is thought to occur immediately after its 
formation as there are no reports of storage granules for the peptide (adapted from 
Rubanyi & Polokoff, 1994). 
ECE - ET converting enzyme 
I Myosin light chain I 
Figure 4. Signaling pathways for ET- 1 evoked vasoconstriction. ET- 1 activates 
ETA and ETs receptors on VSMC leading to PLC mediated production of IP, and 
DAG. The former increases release of Ca2+ fiom the SR and the latter activates 
PKC. ET-1 also directly activates PLD leading to PKC activation. Through these 
signaling pathways, [ca2+li is also increased from the extracellular source through 
opening of Ca*+channels on the plasma membrane. Both increases in [ca2+Ii and 
activation of PKC contribute to the characteristic vasoconstrictor response to ET- 1. 
PLC - phospholipase C; PLD - phospholipase D; DAG - diacylgycerol; PKC - 
protein kinase C; [Ca*+li - cytosolic free CaZ+; SR - sarcoplasmic reticulum 
1.2. Diabetes Mellitus 
1.2.1. Diabetes, insulin, and vascutar disease 
Diabetes Mellitus (DM) is a common metabolic disorder with a worldwide 
prevalence estimated to be between 1 and 5%. After the discovery of insulin, the 
most common cause of mortality and morbidity in diabetic patients involved 
abnormalities of the vasculature occurring in both small and large vessels (King et 
d., 1994). VSMC hypertrophy, polyploidy, and hyperplasia have been demonstrated 
in several models of DM, but the mechanisms behind these abnormalities have not 
been fblly elucidated. Enhanced platelet adhesion and aggregation (Hamet et al., 
l98S), lipoprotein abnormalities (Ramirez et al., 1992), endothelial dysfunction 
(Hsueh & Anderson, 1992), and VSMC abnormalities (Sowers et al., 1993) are all 
proposed contributors to diabetic vascular disease. Numerous reports implicate 
insulin resistance, hyperinsulinemia, and lipid disorders in linking DM to accelerated 
vascular disease (Modan et al., 1 985). 
Non insulin dependent diabetes (NIDDM) is characterized by not only 
hyperglycernia, but also hyperinsulinemia (Reaven, 1988). In conjunction with 
incompletely understood factors, obesity leads to resistance to the actions of insulin 
resulting in hyperinsulinemia. While many of the known actions of insulin have 
been implicated in the progression of vascular disease, significant evidence exists to 
disprove a role for insulin in pathological vascular changes. Not all hypertensives 
are hyperinsulinemic and many patients with hyperinsulinemia and insulin resistance 
are not hypertensive. Furthermore, insulin infusion has been shown to decrease BP 
in dogs (Brands et al., 1991), and to cause vasodilatation in humans (Anderson et al., 
1991). The functional significance of the vasodilator action of insulin is to 
redistribute blood flow to skeletal muscle tissue increasing delivery of glucose to 
these areas. Reports have suggested that insulin induces vasodilation via: a) a neural 
sympathetic effect whereby VSMC contraction to circulating catecholamines is 
reduced in the presence of insulin (Macleod & McNeill, 1985); b) extrusion of 
[ca*+li in VSMC via enhanced cellular ca2+ ATP'ase expression (Sowers et al., 
1993); c) elevation of VSMC steady state membrane potential, via enhanced Na+/K+ 
ATP'ase activity (Tirapattur et al., 1993); d) enhanced p-adrenoceptor mediated 
vasodilatation (Gros et al., 1994); and e) attenuation of agonist evoked Ca*+ 
transients in VSMC's (Touyz et al., 1994). 
Despite this evidence, it is widely thought that chronic hyperinsulinemia contributes 
to vascular pathology. Firstly, if the normal response to insulin is vasodilatation, in 
conditions of insulin resistance, this effect may be blunted. Indeed, the ability of 
insulin to reduce vascular resistance is reduced in obese, hypertensive, and NIDDM 
patients (Baron et a\., 1993). Many early hypotheses attempting to address the role 
of insulin in hypertension focused on renal sodium handling, and sympathetic neural 
actions. An increase in plasma insulin level within or slightly above the 
physiological range greatly reduces fractional sodium excretion (Gans et al., 1991). 
Similarly, acute physiological increases of plasma insulin in healthy humans 
increases muscle sympathetic nerve activity and serum norepinephrine levels 
(Anderson et al., 199 1). 
Recent studies have focused on the cellular actions of insulin in explaining its role in 
vascular pathology. Insulin infusion promotes lipid accumulation (Sato et al., 1989) 
and VSMC hyperplasia (Stout, 1991). The mitogenic effects of insulin in VSMC 
require higher concentrations and longer incubation times than those needed to 
produce metabolic effects (King et al., 1980) and insulin likely mediates most of its 
VSMC proliferative effects through the IGF- 1 receptor, which shows close structural 
homology to the insulin receptor. In addition, insulin may increase responses to 
other hypertrophic stimuli through enhancement of Na+-H' exchange resulting in 
cellular alkalinization (Ferranini et al., 1989). Insulin also exerts atherogenic effects 
by: 1) increasing uptake and esterification of lipoprotein cholesterol by VSMC's and 
decreasing its deesterification and release (Sowers et al., 1993); 2) retarding the 
fibrinolytic process; and 3) stimulation of platelet activator inhibitor (PAI-1) and 
fibrinogen production (Vukovich et al., 1 992). 
In 1991, using cultured bovine aortic EC, it was shown that insulin (1.6 nM) 
increased prepro ET mRNA levels within 2 hours, with maximal effects at 17 nM 
(Oliver et al., 1990). Subsequently, insulin evoked increases in ET-I production 
from human EC and VSMC were confirmed by others (Fem et al., 1995, Anfossi et 
al., 1993). Insulin has also been reported to increase the expression of receptors for 
ET-1 in vitro (Frank et al., 1993), and levels of ET-1 rise during acute 
hyperinsulinemia (Wolpert et al., 1993). Thus, enhancement of ET-1 release and 
action may be another major mechanism by which insulin may alter vascular 
function, and the major thrust of this project is to examine this possibility. 
13.2. The streptozotocin diabetic rat 
STZ is an antibiotic derived from Streptomyces achromogenes; structurally it 
contains a methylnitrosourea group bound to the C2 position of 2-deoxy-d-glucose 
(Tomlinson et al., 1992). Rakieten et al. (1963) was the first to demonstrate that 
STZ, when given intravenously, produced DM in rats and dogs. Rats treated with 
STZ display many of the features seen in humans with uncontrolled DM including 
glycemia, polydipsia, polyuria, and weight loss. The STZ diabetic rat ofien develops 
diabetic complications including myocardial, cardiovascular, tracheal, kidney, 
urinary bladder, vas deferens, adrenal cortex, skeletal bone, connective tissue, and 
neuropathic dysfimctions (Ozturk et al., 1996). The present study utilizes this 
animal model for its lack of plasma insulin and profound changes in endothelial 
b c t i o n  that it exhibits, both of which could be relevant to ET-I release and action. 
1.2.2.1. Mechanism of ST2 induced diabetes 
As with other chemicals used to induce DM, ST2 has a direct toxic action on 
pancreatic P-cells ( h o d  et al., 1969). This toxic effect was shown to begin within 
1 hour after treatment and to lead to massive P-cell degranulation and necrosis 
followed by a transient increase in serum insulin and hypoglycemia. Within 1-2 
days, prolonged hyperglyemia and hypoinsulinemia develop. The mechanism of 
STZ's effect is somewhat controversial, but might involve cellular permeability 
changes, depletion of NAD, alkylation of DNA, nitric oxide and hydroxyl radical 
formation, or release of interleukins and cytokines (Ozturk et al., 1996). The 
depletion of pancreatic kcells limits the ability of the rat to produce insulin and thus 
produces a model of insulin-deficient DM. 
1.2.2.2. Dose of ST2 
The severity of DM obtained in the ST2 rat largely depends on the dose of the agent. 
Doses of 100 mglkg severely deplete pancreatic &cells rapidly causing death (within 
2-3 days) due to a severe ketotic state. These rats require exogenous insulin to 
survive. Doses of 35 mgkg cause only a mild diabetic state. Most cardiovascular 
studies use intermediate doses (in the range of 55-65 mg/kg) that promote 3-4 fold 
higher plasma glucose levels and cause the rats to fail to gain weight. Furthermore, 
these rats are able to survive for months without insulin supplementation. A dose of 
55 mg/kg was chosen in the present study for these reasons. Exogenous 
supplementation with insulin is able to restore plasma glucose, body weight, and 
other metabolic parameters to normal. More importantly, exogenous insulin 
supplementation in these rats is representative of an insulin treated type 1 diabetic 
state, and such treatment would be expected to lead to fluctuations in levels of 
plasma insulin. 
1.2.2.3. Vascular abnormalities 
Of interest to this thesis is the vascular abnormalities produced by ST2 DM. ST2 is 
thought to have profound cardiovascular actions of its own (Tomlinson et al., 1992), 
however, ST2 has a short half-life and is thought to be eliminated completely within 
1-2 days. Most studies examine cardiovascular function not less than 2 weeks after 
DM induction. Thus, the vascular complications in ST2 diabetic rats are thought to 
arise fiom the diabetic state itself. Integrated hemodynarnic studies are lacking in 
ST2 diabetic rats. Due to experimental discrepancies and limitations to current 
methodologies, existing studies are inconclusive as to whether the ST2 rat is 
hypotensive, normotensive, or hypertensive (Tomlinson et al., 1992). Similarly, 
isolated vascular tissue studies are completely inconclusive, as all of increased, 
decreased, and normal vascular responsiveness to vasoactive agonists has been 
observed in STZ rats (Tomlinson et al., 1992). Such disparities are thought to be 
due to inter-study discrepancies in the severity and duration of ST2 DM as well as 
differences in methodologies for measuring vascular function. A relatively 
consistent finding in the vasculature of ST2 rats of relevance to this thesis is the 
presence of marked endothelial dysfunction, manifesting as attenuated EDRF 
mediated vasorelaxation (Pieper, 1998). This effect appears to be dependent on the 
duration of exposure to the diabetic state (Hopfher et al., 1999a) and might involve 
free radical mediated oxidative damage to EC's (Chang et al., 1993), advanced 
glycation end product mediated EDRF quenching (Bucala et al., 199 I) ,  or a direct 
toxic effect of hyperglycemia on the vascular endothelium Clearly, more studies 
are warranted to examine the status of vascular function in ST2 rats, particularly 
integrated hemodynarnic studies that will shed light on the global status of 
cardiovascular function in this model of insulin deficient DM. The present study 
focuses on characterizing responsiveness to ET-1 in isolated vascular tissue fiom 
these rats in an effort to elucidate the in vivo significance of insulinomirnetic actions 
on ET-1 release and action treated diabetic states. 
1.23. Endothelin: Emerging role in diabetic vascular complications 
1.2.3.1. Endothelin-1 in diabetic plasma 
Plasma concentrations of ET-1 in normal individuals range between 1 and 5 pM 
rarely exceeding 25 pM, even in pathological states (Battistini et al., 1993; Frelin & 
Guedin, 2994). This concentration is inadequate to elicit many of the 
pharmacological actions of the peptide. However, the increase (decrease) in ET-1 
plasma levels is thought to reflect overproduction (underproduction) and spillover 
(or lack of) of ET-I from EC (Lerman et al., 1991; Takeda et al., 1991; Wu & Tang, 
1998). Indeed, the majority of endogenous ET-1 is released from EC abluminally 
towards the VSMC (Wagner et al., 1992). Thus, alterations in plasma levels of ET-1 
might be of scientific interest in so far as plasma levels are representative of overall 
cardiovascular production of the peptide. 
The status of ET-1 plasma levels in DM is controversial. The streptozotocin (STZ) 
diabetic rat, a widely used model of insulin deficiency characteristic of IDDM 
(Tomlinson et al., 1992), has been shown to exhibit elevated plasma ET-1 at 8 weeks 
(Tada et al., 1994), 10 weeks (Takeda et al., 199 1; Makino & Karnata, 1998), and 14 
weeks (Hopfher et al., 1999a) after induction of DM. Conversely, these rats have 
also been shown to exhibit either unchanged ET-1 levels at 2 days (Takeda et al., 
199 1) or attenuated levels at 4 days (Takahashi et al., 199 1) and 2 weeks (Hopfber et 
al., 1999a; Frank et al., 1993) after DM induction. Thus, the status of ET- 1 in the 
plasma of ST2 rats appears to be dependent on the pre-existing duration of DM. In 
support of this, our laboratory has recently demonstrated that ET-1 plasma levels in 
ST2 rats are, in fact, differentially altered depending on the pre-existing duration of 
DM - with attenuated levels at 2 weeks, and elevated levels at 14 weeks after 
induction (Hopher et al., 1999a). In patients with IDDM, both elevated (Collier et 
al., 1992; Haak et al., 1 992) and decreased (Smulder et al., 1994; Malamitsi-Puchner 
et al., 1996) plasma ET- 1 has been reported. Decreases in ET-I production in early 
DM might be due to inhibitory effects of hyperglycemia on ET-1 release (Hattori et 
al., 1991), a lack of insulin mediated ET-1 production (Oliver et al., 1 WO), or to 
increased EDRF mediated suppression of ET-1 release (Boulanger and Luscher, 
1990) from the vascular endothelium. Increases in late DM might be due to 
attenuated EDRF mediated suppression of ET- 1 production (Boulanger and Luscher, 
1990), progressive endothelial damage (Vermes et al., 1993), or to elevated 
lipoprotein mediated ET- 1 production (Lennan et al., 1 993). Other factors including 
severity and level of control of DM, presence of macrovascular complications 
(Collier et al., 1992), and methodology for measuring ET-1 (Baumgartner-Parzer et 
al., 1998) might also contribute to these discrepancies. 
1.2.3.2. In vitro vascular reactivity studies 
To date, ex vivo studies examining vascular responsiveness to ET-1 in models of 
DM have yielded equivocal results. Attenuated vasoconstrictor responses to ET- 1 
(but not other agonists) have been observed in vascular tissue from the ST2 rat as 
early as 2 weeks after DM induction (Tada et al., 1994; Makino & Kamata, 1998; 
Fulton et al., 1991; Hodgson & King, 1992). Such selectively attenuated responses 
might be attributed to ET receptor downregulation resulting from either PKC 
activation or elevated ET-1 production (Guillon et al., 1998; Awazu et al., 1991 ; 
Clozel et al., 1993) and can be reversed by either insulin treatment or restoration of 
high glucose in the bathing medium (Hodgson & King, 1992). On the contrary, we 
and others have actually demonstrated increased vasoconstrictor responses to ET- 1 
and other agonists in vascular tissue fiom ST2 rats as early as 2 weeks afier DM 
induction (Hopfher et al., 1 999a; White & Carrier, 1 990; Abebe & Macleod, 1 990). 
Such non-specific increases in vasoconstriction might be attributed to modification 
of contraction resulting fiom either altered Ca*+ channel expression and action 
(White & Carrier, 1990) or PKC activation (Abebe & Macleod, 1990). Importantly, 
we have demonstrated that the trend towards exaggerated responses to ET-1 reverses 
and actually becomes slightly attenuated after long term exposure to DM (Hopfher et 
al., 1999a). This occurs in conjunction with the development of endothelial 
dysfbction and elevated plasma lipid levels - suggesting that attenuated responses 
to ET-1 may take time to develop and may result fkom other pathological processes 
occurring only after long-term exposure to DM. Thus, similar to ET-1 plasma 
levels, the status of vascular reactivity to ET-1 appears to be at least partly 
dependent on the preexisting duration of DM. 
We have also observed exaggerated vasoconstriction to ET- 1 and upregulated ETA 
receptors in aorta fiom obese Zucker rats (Hopfher et al., 1998a). These animals are 
hyperinsulinemic/insulin resistant, mildly hyperglycernic, and hypertensive (Kasiske 
et al., 1992). The Zucker rat is therefore considered an animal model resembling 
NIDDM. Exaggerated vasoconstrictor responses may, however, be non-specific in 
this strain, since similar exaggerated responses were seen with other agonists (Ouchi 
et al., 1996; Hopfher et al., 1998b; Hopfher et al., 1999b). This abnormality has 
previously been attributed to alterations in ~ a * +  channel activity in VSMC (Ouchi et 
al., 1996). 
Most studies examining vascular responsiveness in DM use the aorta, a conduit 
vessel, as the model system. The hazard of correlating large artery tension response 
data with changes in vascular resistance in diabetic states has been outlined in a 
previous review (Todinson et al., 1992). Perfbsed arterial bed preparations have 
been developed which are thought to more adequately represent changes in vascular 
resistance (Christensen & Mulvany, 1993). As such, we (Misurski et al., 1999), and 
others (Makino & Kamata, 1998), have recently demonstrated that the perfused 
mesenteric arterial bed of STZ rats also exhibits altered vasoconstrictor responses to 
ET- 1. 
in summary, in vitro vascular reactivity studies suggest that alterations in 
responsiveness to ET-1 exist in both conduit and resistance type vessels in various 
models of DM. Similar to ET-1 plasma levels, the direction of these changes is 
controversial and might involve DM duration dependent effects as well as 
methodological and other study specific factors. 
1.23.3. In vivo vascular reactivity studies 
While several studies have examined ex vivo vascular responses to ET-1 in diabetic 
animals, few studies have assessed hernodynamic responses to the peptide in vivo. A 
few recent studies in ST2 rats demonstrated that impaired in vivo pressor responses 
to ET-1 appear as early as 2 weeks after DM induction (Lawrence & Brain, 1992; 
Kiff et al., 1991; Guillon et al., 1998). Lawrence and Brain (1992) demonstrated 
attenuated reductions in cutaneous blood flow in response to ET-1 challenge in ST2 
rats - occurring in conjunction with attenuated EDRF action. In contrast, Kiff et. al 
(1991) demonstrated that renal and mesenteric vasoconstrictor responses to ET-1 
were exaggerated in this model. However, initial hindquarter vasodilator responses 
to ET-1 were unchanged, while EDRF production was decreased. Lastly, Guillon et 
al. (1998) recently demonstrated that the in vivo pressor response to ET-I was 
inhibited in ST2 rats by 2 weeks after DM induction, while the response to 
norepinephrine remained unaltered until 5 weeks after induction. These data suggest 
that in vivo reactivity to ET-1 in STZ DM might be dependent on the duration of 
DM, the status of endothelial function and the vascular bed under consideration. 
Only one study to date has assessed in vivo vascular reactivity to ET-1 in human 
diabetic subjects. A lack of sensitivity to the vasoconstrictor effects of locally 
infused ET-1 was demonstrated in forearms of patients with MDDM (Nugent et al., 
1 996). 
1.23.4. Endothelin-1 in specific cardiovascular complicrrtions 
1.23.4.1. Hypertension 
Hypertension occurs in diabetics at a greater incidence than the general population 
and the combination of the two markedly accelerates the atherosclerotic process 
(Hsueh & Anderson, 1992). In IDDM, elevated arterial pressure usually develops 
after, and is thought to result from, nephropathy (Epstein & Sowers, 1992). 
However, in NIDDM, hypertension precedes renal damage but its cause is unknown 
(Epstein & Sowers, 1992). ET-1 is well known to promote sustained elevations in 
BP (Vierhapper et al., 1990) and bosentan, a non-selective ETA/ETB antagonist, has 
recently been shown to lower BP in essential hypertensives (Krum et al., 1998). 
Haak et. a1 (1992) first demonstrated that elevated plasma ET-1 acts as a marker of 
hypertension in IDDM patients. Studies in NIDDM do not support such a link. 
While plasma ET-1 was shown to be elevated in NIDDM, those with both 
hypertension and macrovascular disease, but not with hypertension alone, exhibited 
higher plasma ET- 1 than those with uncomplicated NIDDM (Perfetto et al., 1997). 
1.2.3.4.2. Atherosclerosis 
Atherosclerotic vascular disease occurs in diabetics at a rate much higher than that of 
the general population and macrovascular complications resulting from 
atherosclerosis are responsible for the greatest number of deaths associated with the 
disease (Hsueh & Anderson, i 992). Altered endothelial function ultimately leads to 
VSMC proliferation - an integral feature of atherosclerosis (Hsueh & Anderson, 
1992). ET-1, being a potent and highly efficacious VSMC growth promoting 
peptide, might play an important role in this process. Atherosclerotic human 
arteries were shown to exhibit downregulated ET receptor mRNA, but upregulated 
ET-I peptide mRNA (Winkles et al., 1993). A recent study demonstrated that the 
non-selective ETA/ETB receptor antagonist, bosentan, prevented neo-intima 
formation in a rabbit carotid artery model of atherosclerosis (Marano et al., 1998). 
Lennan et. a1 (1991) provided compelling evidence that ET- 1 production and ET-1 
plasma levels are elevated in patients with atherosclerosis. Later studies confirmed 
that elevated plasma ET-1 is indeed a marker of atherosclerotic macrovascular 
disease in patients both with and without NIDDM (Perfetto et al., 1997; Perfetto et 
al., 1998). Furthermore, those with the highest ET-1 levels had both atherosclerosis 
and NIDDM (Perfetto et al., 1998). Thus, considerable evidence indicates that ET- I 
might be involved in the atherosclerotic process. 
1.23.4.3. Neurovascular abnormalities 
An early reduction in blood flow to peripheral nerves leading to endoneurial hypoxia 
contributes to nerve conduction deficits in DM (Tuck et al., 1984). Studies in STZ 
rats have established a possible role for ET-1 in the etiology of attenuated 
endoneurial blood flow in DM. Sciatic axons of STZ rats were shown to be 
selectively susceptible to ET-1 induced ischaemia (Zochodne et al., 1998). This was 
partly accounted for by more intense and prolonged vasoconstriction to the peptide - 
suggesting that ET-1 might contribute to nerve perfusion deficits in DM. In support 
of this, sciatic nerve motor conduction deficits in diabetic rats could be improved by 
2 weeks of treatment with the ETA antagonist, BQ123, in association with an 
increase in sciatic nutritive endoneurial blood flow (Cameron et al., 1994). 
However, non-selective ETA/ETB blockade with bosentan failed to evoke similar 
actions (Stevens & Tomlinson, 1995), indicating that the addition of ETB blockade 
might blunt the beneficial effects of ETA antagonism. The addition of an 
angiotensin ATI receptor antagonist to diabetic rats already treated with an ETA 
antagonist resulted in synergistic beneficial effects on nerve conduction (Cameron & 
Cotter, 1996). Thus, there is considerable evidence that an increased 
vasoconstrictive capacity to ET-I is present in the neurovasculature of diabetic 
animals, and importantly, antagonists of the ET system appear to beneficially affect 
neurovascular function in these animals. 
1.2.3.4.4. Retinopathy 
Abnormal retinal hernodynamics in both human and animal models of DM 
contributes to the development of diabetic retinopathy (Kohner et al., 1995). Ocular 
tissue appears to be a rich source of ET-I peptide expression. Production of the 
peptide occurs in both vascular and extravascular tissues in the retina, uveal tract, 
and optic nerve (MacCumber et al., 1991). Accordingly, alterations in ET-1 
production and action have been hypothesized to contribute to diabetic retinopathy 
and other ocular vascular diseases (Pang & Yorio, 1997). Several in vitro studies 
have demonstrated that high glucose levels can alter both production and responses 
to ET-I in pericytes - the contractile cells of the retinal microcirculation. Exposure 
to elevated glucose levels attenuated ET-1 evoked cellular signaling and contractile 
responses in rat retinal pericytes (de la Rubia et al., 1992; Chakravarthy et al., 1994). 
Later studies showed that increases in retinal circulation time after intravitreal 
injection of ET-I and ET-3 were attenuated (Bursell et al., 1995) in STZ rats and 
that altered retinal blood flow in these rats could be normalized by phosphoramidon, 
an ECE inhibitor (Takagi et al., 1996). PreproETmRNA was also increased 2-fold 
in the retina of diabetic rats compared to normal controls. These results implicate 
increases in the endogenous production of ET-1 as well as changes in sensitivity to 
ET-I resulting in altered retinal blood flow in DM. There are few studies assessing 
the role of ET-I in diabetic retinopathy in humans. One recent study demonstrated 
that ET-1 levels in the vitreous fluid of diabetic patients with proliferative 
retinopathy are actually decreased compared to non-diabetic controls (Ogata et al., 
1998). Moreover, elevated plasma ET- 1 has been observed in NIDDM patients with 
retinopathy (Kawarnura et al., 1992; Laurenti et al., 1997) but without other DM 
related end-organ damage. Thus, there is considerable evidence indicating the 
presence of alterations in ET-1 peptide and receptor expression and action in the 
diabetic eye that could be relevant to the pathogenesis of diabetic retinopathy. 
1.23.4S. Nephropathy 
The kidney is an important site of action for ET-1 (Laurenti et al., 1997). 
Glomerular EC, mesangial cells, and epithelial cells secrete ET-I . ET-1 constricts 
renal vessels, contracts mesangial cells, inhibits salt and water reabsorption, 
enhances glomerular proliferation, and stimulates extracellular matrix accumulation. 
While basal tone is only modestly maintained by ET-1, pathophysiological levels of 
ET-1 cause profound renal vasoconstriction with little effect on systemic BP 
(Sorenson et al., 1994). 
Alterations in urinary (Morabito et al., 1994; Turner et al., 1997) total renal (Shin et 
al., 1995; Vesci et al., 1995), glomerular (Fukui et al., 1993), and ureteraI 
(Nakamura et al., 1997) ET-1 peptide, preproET mRNA, and ET receptor levels are 
present in animal models of  DM. Studies with ET antagonists have also 
demonstrated a role for this peptide in renal dysfunction in DM. 24 weeks of 
treatment with the ETA receptor antagonist, FR139317, attenuated the fall in 
creatinine clearance and reduced urinary protein excretion and mRNA expression for 
extracellular matrix components and growth factors in glomeruli of ST2 rats 
(Nakarnura et al., 1995). Another ETA antagonist, LU13SZ52, decreased elevated 
urinary ET-1 in STZ rats while having only modest effects on albumin excretion 
(Hocher et al., 1998). The non-selective ETA/ETB receptor antagonist, PD142893, 
normalized renal blood flow, and reduced urinary protein and albumin excretion in 
proteinuric ST2 rats to a similar extent as the ACE inhibitor, enalapril (Benigni et 
al., 1998). Once again, there are few studies examining renal ET-1 in humans. 
Elevated 24 hr urinary ET-1 was present in NIDDM patients with alburninuria (Lee 
et al., 1994) and elevations in circulating ET- 1 preceded the microalbuminuric phase 
of DM related renal damage (de Mattia et al., 1998). Thus, it is clear that alterations 
in urinary and renal ET-1 content are associated with diabetic nephropathy and this 
is another complication where ET antagonists have demonstrated protective effects. 
1.2.3.4.6. Cardiac disease 
The cardiac actions of ET-1 have been well characterized. Local administration of 
ET- 1 to coronary vessels induces marked vasoconstriction resulting in signs of 
myocardial ischemia (Miyauchi & Masaki, 1999). It also confers positive 
chronotropic and inotropic actions, and may be arrythmogenic. ST2 DM is 
associated with reductions in mechanical performance of the heart, and changes in 
responsiveness to various stimuli have been reported in this model (Tahiliani & 
McNeill, 1986). Radioligand binding studies revealed a decrease in cardiac ET- 1 
binding sites in ST2 rats as early as 3 days after DM induction (Nayler et al., 1989). 
Positive chronotropic and inotropic actions of ET-1 in right and left atria are also 
reduced in STZ rats (Lieu & Reid, 1994). Plasma ET- 1 levels were shown to be 
elevated in NIDDM, there was no further increase in those patients with concomitant 
coronary artery disease (Donatelli et al., 1994), indicating that elevated ET- 1 levels 
might precede cardiac disease in NIDDM. Moreover, a recent study demonstrated 
that NIDDM patients exhibited elevated coronary sinus blood ET-I levels during 
reperfusion subsequent to coronary artery bypass graft surgery (Fogelson et al., 
1998). It was suggested that this alteration might contribute to the increased 
prevalence of cardiac morbidity and mortality observed in NIDDM patients after this 
procedure. 
1.23.5. Metabolic variables influencing ET-1 production and action 
From the above evidence, it is clear that the diabetic state is associated with changes 
in the release and action of ET-1 in nearly all of the target sites affected by the 
disease. The question that remains is - what factors in DM are responsible for such 
changes? Due to the plethora of metabolic and cardiovascular abnormalities present 
in IDDM and NIDDM and differential effects of the various treatment options on 
these variables, isolating the causes of changes in ET-1 release and action assumes 
importance. 
1.2.3.5.1. Hy perglycemia 
Hyperglycemia, the primary metabolic disturbance of DM, has been shown to 
increase (Yarnauchi et al., 1990), decrease (Hattori et al., 1991), and have no effect 
on (Baumgartner-Parzer et al., 1994; Metsarrine et al., 1994) the release of ET-1 
from EC in culture. Species differences as well as the level and duration of 
incubation of glucose employed by these studies might account for these 
discrepancies. Studies on the effect of high glucose on receptors for ET-1 have also 
yielded somewhat equivocal results. Incubation of cultured aortic smooth muscle 
cells (ASMC) with high glucose has been shown to decrease the maximal binding 
capacity (but not affinity) for ET-1 (Frank et al., 1993; Sandirasegarane et al., 
1994). In contrast, pericytes incubated with high glucose exhibited no significant 
changes in receptors for ET-1 (de la Rubia et al., 1992). Studies in both retinal 
pericytes (de la Rubia et al., 1992; Chakaravarthy et al., 1994) and ASMC 
(Sandirasegarane et al., 1994) have also revealed that contractile responses to ET-1 
are blunted after high glucose incubation, apparently independent of effects on 
receptor expression. Thus, high glucose may regulate the release of ET-1 as well as 
responses to the peptide at both the receptor and post-receptor level (Figure 5). 
Further studies using hyperglycemic clamps are warranted to determine the 
significance of these findings in vivo. 
1.2.3.5.2. Insulin 
NIDDM is often considered a hyperinsulinemic state and IDDM patients on insulin 
therapy exhibit fluctuations between insulinemia and glycemia. Since the seminal 
discovery that insulin increases gene expression for ET-I in cultured EC (Oliver et 
al., 1990), intense research has focused on elucidating the relevance of this effect in 
pathological states characterized by elevated or fluctuating insulin levels. It was 
confirmed that physiological insulin concentrations could increase the release of ET- 
1 fiom both EC (Metsarrine et al., 1994; Ferri et al., 1995) and VSMC (Anfossi et 
al., 1993) in culture. Later studies went on to show that induction of 
hyperinsulinemia increased plasma levels of ET-1 in both humans (Ferri et al., 1995; 
Piatti et al., 1996) and animals (Frank et a]., 1993). Other studies have, however, 
failed to show such an effect (Metsarrine et al., 1994; Leyva et al., 1997). 
Studies have also demonstrated an effect of insulin on changes in tissue reactivity to 
ET-1, both at the receptor, and post receptor level. It was fust demonstrated in 1993 
that incubation of ASMC with high concentrations of insulin increased ET receptor 
expression, and that 2 weeks of in vivo insulin delivery to normal and ST2 rats was 
associated with increases in kidney, brain, and ASMC ET receptors (Frank et al., 
1993). The present study confms  these results demonstrating that long-term insulin 
incubation of rat ASMC selectively increases ETA receptor expression and that 
upregulated receptors are coupled to increases in ET- I evoked [Ca2+] elevations. 
Furthermore, we demonstrated that aorta fiom the hyperinsulinemic/insulin resistant 
obese Zucker rat exhibit increased ETA receptor expression, suggesting possible 
physiological relevance of these findings. This was supported by a recent study 
demonstrating that hyperinsulinemic fructose hypertensive rats exhibit increased tail 
artery ETA receptor expression (Juan et al., 1998). In contrast, acute incubation of 
VSMC with insulin appears to have a suppressive effect on ET- 1 (as well as other 
agonists) evoked increases in [Ca*+Ji levels. In the presence of supraphysiological 
insulin concentrations, ET- I evoked contraction of cultured rat mesangial cells was 
attenuated (Inishi et al., 1994). In support of this, it was later demonstrated that 
porcine coronary artery [ca*+li responses to ET-1 were attenuated in the presence of 
a physiological insulin concentration (Dick & Sturek, 1996). The functional 
relevance of these observations is evident in a recent study demonstrating that 
insulin attenuates ETA receptor mediated coronary contraction through an 
endothelium independent mechanism (Hasdai et al., 1998). However, another recent 
study using endothelium intact rat aortic rings demonstrated that, in the presence of 
insulin, arterial contraction induced by KC1 was exaggerated, and this was 
normalized in the presence of ET blockers (Nava et al., 1997). Thus, fiom the 
available evidence, it appears that the effect of insulin on VSM responsiveness to 
ET-1 in vitro depends on both the term of exposure to insulin, as well as on the 
presence or absence of intact endothelial function for the release of ET-1. In 
summary, insulin appears to be a modulator of ET-1 peptide, ET receptors and ET- 1 
mediated responses - both in vitro and in vivo (Figure 6). 
1.23.53. Lipoproteins 
Elevated plasma lipoproteins are present in both IDDM and NIDDM patients, 
particularly in those with poor metabolic control (Epstein & Sowers, 1992). A 
similar profile exists in diabetic animal models. The Zucker rat exhibits elevated 
plasma lipids (Kasiske et al., 1992), and the STZ rat develops hyperlipidemia and 
hypercholesterolemia after only a few weeks of exposure to DM (Hopfner et al., 
1999a). Significant evidence indicates a profound ability of plasma lipoproteins to 
affect both the release and action of ET-I. Oxidized LDL was shown to evoke a 
concentration and time dependent increase in preproETmRNA expression in porcine 
and human EC (Boulanger et al., 1992). Subsequent studies confirmed that only high 
concentrations of native VLDL and LDL would have a similar effect (Horio et al., 
1993). Several in vivo studies have substantiated these findings. Elevated plasma 
lipids were shown to elevate EC (Uyama et al., 1996), coronary (Lerman et ai., 
1993), and plasma (Lerman et al., 1993; Piatti et al., 1996), ET-1 levels in vivo. 
Furthermore, the effect of hyperlipidemia on plasma ET-1 was synergistic with 
hyperinsulinemia (Piatti et al., 1996). Accordingly, plasma ET-1 has been shown to 
be elevated in patients with elevated plasma lipoproteins (Haak et al., 1994) even 
before the development of atherosclerosis (Magniafico et al., 1996). 
Similar to observations with insulin and glucose, elevated lipids also appear capable 
of altering VSM responsiveness to ET-I. It was demonstrated that 
hypercholesterolemic rabbits exhibit exaggerated vascular reactivity to vasoactive 
peptide agonists, including ET-1, before the development of endothelial dysfunction 
(Merkel & Bilder, 1992). In addition, pigs fed a high cholesterol diet for 10 weeks 
exhibited accentuated coronary vasoconstrictor responses to ET- 1 without exhibiting 
changes in epicardial coronary artery ET receptor density or affinity (Matthew et al., 
1997). Thus, similar to both insulinemia and hyperglycemia, hyperlipidemia per se 
has the capability to increase plasma levels of ET-I as well as receptors and tissue 
reactivity to the peptide (Figure 7). 
1.2.3.5.4. Endothelial dysfunction and duration of disease. 
The nature of endothelial dysfunction in DM is controversial. It has been 
hypothesized that elevated EDRF production occurs in DM due to hyperglycemia 
mediated nitric oxide synthase (NOS) activation (Wascher et al., 1994; Pieper, 
1998). However, it is also well established that the metabolic dysregulation of DM 
is associated with inhibition of EDRF release and action through a multitude of 
direct and indirect actions (Figure 8; Pieper, 1998). Significant evidence implicates 
differences in the duration of exposure to DM in determining the nature and 
direction of these changes. While hyperglycemia might activate EDRF production 
acutely, as the duration of DM progresses, atherosclerotic (Hsueh & Anderson, 
1992) and other events such as advanced glycation end product (Bucala et al., 199 1) 
and superoxide radical (Chang et al., 1993) formation clearly promote pathological 
changes in endothelial b c t i o n  leading to suppressed EDRF action. In support of 
this concept, a recent study demonstrated that EDRF mediated vasodilatation is 
accentuated in 2-week ST2 rats, but becomes paradoxically impaired as the duration 
of DM progresses (Pieper, 1999). Moreover, we have recently established that 
EDRF mediated vasodilatation is attenuated in 14 week, but not 2 week, ST2 rats 
(Hopfher et al., 1999a). 
Alterations in EDRF in DM could significantly affect ET-1 activity. EDRF is well 
known to suppress ET-1 release (Boulanger and Luscher, 1990) and endothelial 
damage itself is thought to be associated with increased release of ET-1 (Lerman et 
al., 1991 ; Takeda et al., 1991). Moreover, ET receptor blockade in a model of 
atherosclerosis was recently shown to restore EDRF mediated endothelial hnction - 
suggesting that ET-I may act to inhibit EDRF in pathological states (Barton et al., 
1998). Such a link between changes in EDRF and endothelial function and the 
release and action of ET-1 likely has a profound effect on ET- 1 activity in DM. 
Accordingly, as DM progresses from diagnosis to end stage, changes in ET-1 release 
and action may vary in parallel with changes in EDRF and endothelial function. 
Indeed, we have shown that changes in plasma levels of ET-1 and vascular 
responses to ET-1 in ST2 rats are duration dependent and occur in parallel with 
changes in endothelial bc t ion  (Hopfher et al., 1 999a). 
1.2.3.5.5. Summary - metabolic variables 
In summary, it is clear that many of the well-known metabolic abnormalities 
encountered in DM contribute individually and synergistically to alterations in the 
release and action of ET-I both in vitro and in vivo. Further studies examining how 
ET blockers affect the sequelae of each of these abnormalities are required to 
determine the physiological relevance of these actions. Furthermore, examining 
how these factors interact in vivo and how current treatment options for the 
metabolic dysregulation of DM act to modulate ET-1 activity also assumes 
importance. 
1.2.3.6- Conclusions 
The diabetic state is associated with a multitude of metabolic abnormalities that are 
capable of directly and indirectly contributing to endothelial and VSM dysfunction. 
Alterations in both the release and action of ET-1 are clearly present in various 
models of DM. However, the nature and direction of many of these changes is 
controversial. Nonetheless, the important role of ET-I as a modulator of vascular 
tone and growth indicate that any such changes might have important 
pathophysiological consequences in the development of diabetic vascular 
complications. Antagonists of the ET system are rapidly progressing to the clinic for 
the treatment of cardiovascular disorders including congestive heart failure and 
pulmonary hypertension. Groundbreaking recent studies in diabetic animal models 
indicate that blockers of the ET system might beneficially affect, and even 
ameliorate some of the cardiovascular complications of DM - notably nephropathy, 
and neuropathy. Future studies will determine the role of the ET system in other 
complications of DM and whether these actions are relevant to human DM. Such 
studies might provide rationale for the clinical use of ET antagonists in DM. 
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Figure 5. Effects of high glucose on factors related to ET-1 production and action. 
Glucose regulates ET-1 peptide and receptor expression as well as responses to the 
peptide in viho. However, the direction of these changes is controversial. High 
glucose also increases EDRF production through activation of nitric oxide synthase. 
It also inhibits EDRF via endothelial damage and other actions such as advanced 
glycation end product and superoxide radical formation. Such actions on EDRF 
could also regulate ET- 1 production and action. 
EDRF - endothelium derived relaxing factor; EC - endothelial cell; VSMC - 
vascular smooth muscle cell. 
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Figure 6. Effects of insulin on factors related to ET-1 production and action. 
Insulin increases ET- 1 peptide production via gene activation of ET- 1. Insulin also 
selectively upregulates ETA receptors on VSMC after long-term incubation, and 
enhances subsequent [Ca*+Ii responses to ET-1. In contrast, short-term incubation 
of VSMC with insulin actually attenuates ET-1 evoked [ca*+Ii responses. Insulin 
also increases EDRF formation via nitric oxide synthase activation. 
Figure 7. Effects of lipoproteins on factors related to ET-1 production and action. 
Oxidized low-density lipoproteins increase ET-1 gene expression and elevated 
lipoproteins in vivo accentuate vascular responses to agonists (including ET-1) 
before the onset of atherosclerosis. In atherosclerotic blood vessels, ET receptors 
are decreased and ET-1 peptide increased. Moreover, endothelial damage resulting 
fkom the cascade of atherosclerotic events resulting fkom dyslipidemia would be 
expected to modulate the release and action of ET-I. 
LDL - low density lipoprotein 
Figure 8. Inter-relationships between ET-1 and EDRF. ET-1 is the main 
vasoconstrictor/mitogenic mediator released by the vascular endothelium whereas 
EDRF modulates vasodilatation/anti-growth effects. EDRF inhibits ET- 1 release at 
the gene level. Conversely, ET-1 might inhibit EDRF in pathological conditions. 
Thus, factors that regulate one system can be expected to affect the other. The 
metabolic dysregulation of DM has profound effects on both EDRF and ET-1 
release and action. Such inter-dependence might be evident in early and late stage 
DM where changes in endothelial and EDRF function appear to coincide with 
changes in ET- 1 release and action. 
1.3. Vanadium Compounds 
1.3.1. Insulinomimetic effects 
1.3.1.1. In vitro 
Vanadium is a transition metal found in abundance in nature (0.02% of earths crust). 
It has an extremely complex chemistry and can readily change its oxidation state and 
take an anionic or cationic form (Rehder, 1992). The first evidence that vanadium 
could iAnfluence a biological system came in 1977, when its in vitro inhibitory action 
on Nat/K+ ATP'ase was described (Cantley, 1977). The insulinomimetic effects of 
vanadium was first described in 1979, when vanadate was shown to increase glucose 
transport and oxidation in adipocytes, to stimulate glycogen synthesis in liver and 
diaphragm, and to inhibit gluconeogenesis in hepatocytes (Tolman et al., 1979). 
Since then, vanadium has been found to mimic most of the biological effects of 
insulin in various cell types. Vanadate, the V+s oxidation state of vanadium, 
exhibits insulinomimetic effects in various tissues a s  follows - Vanadate: 1) 
accelerates glycolysis by inhibiting fructose 2,6 bisphosphatase, and inducing the L- 
type pyruvate kinase gene (Miralpeix et al., 1991); 2) decreases mRNA for 
phosphoenolpyruvate carboxykinase (PEPCK), the rate limiting enzyme in 
gluconeogenesis (Bosch et al., 1990); 3) promotes glycogen deposition in 
hepatocytes; 4) recruits glucose transporters to the plasma membrane (Paquet et al., 
1992); 5) activates lipogenesis, inhibits lipolysis and increases the release of 
lipoprotein lipase from adipose tissue (Ueki et al., 1989); and 6) enhances glucose 
uptake, glycolysis, and glycogen synthesis to a lesser extent than insulin, but causes 
a greater stimulation of lactate and glucose oxidation (Clark et al., 1985). 
13.1.2. In vivo 
The antidiabetic effects of vanadate in vitro prompted in vivo experiments. The 
demonstration of its efficacy by Heyliger et al. (1985) was the beginning of 
numerous studies in animal models of DM. The most marked effects of vanadate are 
seen in ST2 rats, where oral administration of vanadate causes a fall in blood 
glucose levels within 2-5 days. Efficacy of treatment appears to be inversely related 
to the severity of DM and persists for up to one year. In addition, the antidiabetic 
effects of vanadate have been shown in genetically obese, hyperinsulinemic, and 
insulin resistant rats and mice (Meyerovitch et al., 1991; Brichard et al., 1989). 
Recently, two groups have done small scale clinical studies on the antidiabetic 
effects of vanadate (Goldfine et al., 1995, Cohen et al., 1995). The dose of vanadate 
used was much lower than previous studies in animals, and treatment periods were 
up to 3 weeks. In IDDM patients, no consistent influence on the glycemic control 
could be detected, but daily insulin requirements decreased significantly. In 
NIDDM, insulin sensitivity increased during vanadium treatment, via greater 
inhibition of hepatic glucose production by insulin and from a greater stimulation of 
peripheral glucose disposal. Most of these metabolic effects persisted for up to 2 
weeks following cessation of treatment. 
1.3.2. Cellular actions 
The cellular actions of vanadate relevant to its insulinomimetic effects are depicted 
in Figure 9. Vanadate permeates the intestinal wall and cell membranes via either 
passive diffusion or by means of an anion camer system (Cantley, 1977). Once 
inside the cell, vanadate is converted primarily to the vanadyl (V+4 oxidation state) 
form. The insulin like properties of vanadate have been ascribed to increased 
phosphorylation of the insulin receptor by inhibition of phosphotyrosyl phosphatase 
(Swamp et al., 1982). Vanadate could also act at sites distal to the insulin receptor. 
This view is supported by several observations: 1) Insulin like effects of vanadate 
remain in adipocytes depleted of insulin receptors (Green, 1986); 2) Vanadate 
evoked phosphorylation of the insulin receptor is weak (Mooney et al., 1989); 3) 
Vanadate stimulation of MAP kinase is independent of insulin receptor 
phosphory lation (D90nofrio et al., 1 994); and 4) Vanadate activates a cytosolic 
insulin insensitive tyrosine kinase (Elberg et al., 1994). Taken together, these 
observations indicate that vanadate might be active in influencing glucose 
metabolism even when insulin signaling pathways are not functioning correctly. 
This could have obvious benefits in NIDDM, with its hallmark insulin resistance. 
1.3.3. Toxicities 
Concerns about toxicity have hampered research on the development of vanadium as 
a treatment for diabetics. Blood levels of vanadium average about 20 p M  in 
diabetic animals chronically treated with oral vanadium, a level 100-fold greater 
than in untreated controls. Higher concentrations may be reached in bone and 
kidneys, where vanadium accumulates (Brichard & Henquin, 1995). The most 
prevalent side effect of vanadium is gastrointestinal intolerance and an anorectic 
effect. With some exceptions, long term oral vanadium treatment has not been 
shown to affect haematological indices or to alter renal or hepatic bc t ion .  There is 
little toxicological data regarding chronic vanadium treatment in humans. One of 
the major concerns of vanadate is its known contractile effect on both VSM and non- 
VSM tissue (Sunano et al., 1988; Laniyonu et al., 1994). 
1.3.4. Cardiovascular actions 
Dr. Hollenberg and associates have established that vanadate contracts rat aorta by 
promoting ~ a * +  influx via activation of protein tyrosine kinase (Laniyonu et al., 
1994). Our laboratory has shown that vanadate enhanced [caZfli levels in rat 
ASMC with an ECSO of 42 2 11 pM; this is closely parallel to the ECso value for its 
vasoconstrictor effect on aortic rings (Sandirasegarane & Gopalakrishnan., 1995). In 
agreement with in vitro reports, several studies have shown an increased vasopressor 
response to vanadate in vivo (Voelkel & Czartolomna, 1991 ; Steffen et al., 1981). In 
apparent contrast to these reports, Dr. John McNeill's laboratory reported that oral 
administration of vanadyl sulfate or an organic vanadyl compound reduced blood BP 
in both fiuctose induced hypertensive rat and spontaneously hypertensive rat models, 
but not in normotensive strains (Bhanot & McNeill, 1994; Bhanot et al., 1994). 
They hypothesized that correction of insulin resistance and subsequent 
hyperinsulinemia in these strains was responsible for this effect. It is one intent of 
this project to further explore the contractile effects of vanadate at the cellular and 
whole animal level in relation to ET-1 evoked alterations in vascular tone in an 
attempt to fully characterize the potential toxicity of this clinically useful insulin 
sensitizing agent. 
Figure 9. Signaling pathways for insulin dependent and insulin independent cellular 
actions of vanadate. Vanadate gains access to cells in the V03- form via either 
passive diffusion or by means of an anion carrier system. Once inside the cell, 
vanadate is converted to the vanadyl form. Through inhibition of protein tyrosine 
phosphatases, vanadate can either enhance insulin mediated phosphorylation of the 
insulin receptor (insulin-dependent action), or activate cytosolic tyrosine kinases 
(insulin-independent action) coupled to PLCy activation and the subsequent cascade 
of events leading to increases in [&*+Ii. 
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2. PRESENT INVESTIGATION 
2.1. General 
The diabetic state is associated with alterations in vascular function that contribute to 
the well-known cardiovascular complications of the disease. Recent studies have 
outlined a potential role for the ET system in contributing to these complications. It 
is also evident that some of the treatment options - including insulin and vanadate - 
for DM might not only correct the metabolic abnormalities responsible for this 
degradation in cardiovascular function, but may adversely affect cardiovascular 
function themselves. In light of the well-established interactions between insulin 
and ET- I ,  it is important to extensively examine the relationship between these two 
peptides. Moreover, while many studies have addressed the role of insulin in 
promoting the release of ET- 1 both in viva and in vitro, few studies have addressed 
the role of this important metabolic hormone in regulating receptors for, and 
responses to ET-1 at the VSM level. With these premises, this thesis addresses the 
role of both insulin, and the insulinomimetic agent, vanadate, in regulating ET 
receptors in vitro, and the consequences of these effects under treatment conditions 
in type I diabetic states. 
2.2. Hypothesis 
1. Long-term preincubation of ASMC in culture with both insulin and vanadate 
upregulates cell surface ET receptors. The subcellular mechanism initiating this 
response is tyrosine kinase phosphorylation, since both insulin and vanadate 
activate this process by direct coupling to cell surface tyrosine kinase linked 
receptors and inhibition of protein tyrosine phosphatases, respectively. 
2. Insulin and vanadate induced upregulation of ET receptors on ASMC is coupled 
to enhanced ET agonist induced [ca*+Ii responses as well as enhanced 
expression of ETA and ETB rnRNA. This effect is specific to ET receptors, as 
responses to Ang I1 and AVP remain unchanged. 
3. Vascular tissue isolated from ST2 diabetic rats exhibits selectively attenuated 
responses to ET-1, since severe insulin deficiency would remove the 
upregulatory influence of this hormone on ET receptor expression in vivo. 
4. Long-term in vivo treatment with insulin or vanadate will normalize attenuated 
ET-1 evoked vasoconstrictor responses in vascular tissue from STZ rats by 
restoring the insulinomimetic influence on ET receptor upregulation. Similarly, 
insulin and vanadate treatment will promote exaggerated responses to ET-1 in 
vascular tissue fiom non-diabetic controls. 
23. Rationale and objectives 
The major emphasis of this project was to provide insight into the role of 
insulinomimetics in modulating ET activity both in vitro and in viva Isolated 
ASMC in culture were used to examine the in vitro effect of insulinomimetic 
pretreatment on ETA and ETB receptor binding and mRNA expression, as well as on 
ET-1 induced [Ca2+Ii regulation. Interestingly, past studies have shown attenuated 
agonist evoked [Ca2+Ji responses in ASMC in the presence of insulin (Touyz et al. 
1994; Standley et al. 1991). However, other studies have shown that long term 
preincubation with insulin actually increases ET receptor expression on VSMC 
(Frank et al., 1993). We proposed that after longer term preincubation with insulin, 
ET-1 evoked [ca2+Ii would, in fact, rise due to upregulation of ASMC ET receptors. 
In addition, the effect of vanadate on these parameters was also measured since no 
studies have examined vanadate's effects on ET activity in any cell line. 
The second major focus of this project was to determine the effect of insulin and 
vanadate on ET-1 release and action under treatment conditions in diabetic and non- 
diabetic states. If insulin and vanadate affected ET receptor expression in vitro, we 
were interested in determining whether similar effects could be seen in vivo. To this 
end, ET-1 evoked vasoconstrictor responses were determined in vascular tissues 
derived fiom insulin and vanadate treated rats. Most studies to date that have 
examined the effects of insulin on ET-1 production and action in vivo have been 
done using short-term insulin treatment (ie. hyperinsulinemic clamp). We deduced 
that the physiological situation would be more precisely mimicked if subjects were 
pretreated with insulin for a longer time period. Thus, rats were treated for a period 
of 14 days using continuous delivery of insulin or oral delivery of vanadate after 
which vascular reactivity and plasma ET-1 measurements were made. 
2.4. Basic Design 
2.4.1. Specific Aims 
2.4.1.1. Aim 1 
The first aim of the study was to elucidate the effect of insulin pretreatment on ET 
receptor expression and ET evoked [Ca2+Ji changes in ASMC in culture. To these 
ends, three types of experiments were performed: 
Receptor binding studies 
Measurement of [Ca2+Ii changes in dispersed ASMC 
ETA and ETB mRNA measurements using northern blot methodology 
It was important to ascertain whether other vasoactive peptides would elicit similar 
responses after insulin pretreatment. Therefore, in addition to the main focus on ET- 
1, additional [ca*+Ii studies were carried out utilizing two other potent vasoactive 
peptides, Ang I1 and AVP. 
2,4.1.2. Aim 2 
The second aim of the study was to simply compare the in virro effects of insulin 
with those of the well-known insulinomimetic, vanadate. It is important to 
determine whether insulinomimetics acting through different mechanisms (than 
insulin) would evoked similar actions as insulin on ET receptor expression and 
action. Accordingly, all of the above experiments with insulin were carried out in 
parallel with vanadate. 
2.4.1.3. Aim 3 
The final, and most physiologically relevant aim of the study was to investigate the 
effects of longer-term in vivo insulin and vanadate treatment on ET- I release and 
action in diabetic and non-diabetic animal models. To this end, both STZ diabetic 
and non-diabetic rats were treated with insulin and vanadate for a period of 2 weeks 
after which vasoconstrictor responses to ET-1 in vascular tissue ex vivo and plasma 
levels of the peptide were measured. Once again, since it was important to 
determine whether any of the observed effects of these compounds was specific to 
ET- 1, we also measured vasoconstrictor responses to methoxamine (a -adrenergic 
agonist) and vasodilator responses to ACh, an endothelium dependent vasodilator. 
2.4.2. Specific experimental objectives and design 
2.4.2.1. Animal models 
Towards the aforementioned receptor binding, [ca2+Ji, and mRNA measurements, 
ASMC derived from agelsex matched 10 to 12-week old male SD rats were 
employed. For in vivo studies, age and sex matched Sprague-Dawley (SD) control 
(non-diabetic) and ST2 treated (diabetic) rats were employed. 
2.4.2.2. In vitro studies 
2.4.2.2.1. Receptor binding 
It has previously been shown that insulin pretreatment upregulates ETA receptors on 
VSMC's (Frank et al., 1993). However, there has been no attempt to differentiate 
the receptor subtype involved in insulin evoked ET receptor upregulation in rat 
ASMC's. In addition, vanadate's effects on ET receptor regulation has yet to be 
documented, which assumes importance in light of its known contractile effects on 
VSM (Sunano et id., 1988, Laniyonu et al., 1994). Thus, the effects of insulin and 
vanadate on ET receptor binding parameters in ASMC was first examined. 
Saturation binding studies utilized radiolabeled ET- 1 (ETA/ETB non-selective 
agonist), and IRL-1620 (ETB agonist) to determine the density of maximal binding 
sites (B,) and the equilibrium dissociation constant or affinity (KD). The likely 
role of insulin and vanadate on ET receptor binding in ASMC was then assessed. 
Preliminary studies involved pretreatment of ASMC in vitro with insulin and 
vanadate for given time periods to determine the optimal time and concentration of 
pre-incubation which upregulates [I2511 ET-1 binding to the maximal extent. Once 
optimal conditions were established, saturation studies were performed and ETA and 
ETB sites per cell were ascertained. It is widely accepted that insulin exerts its 
effects through tyrosine kinase linked receptor activation promoting phosphorylation 
of several intracellular proteins involved in eliciting the actions of insulin. In 
addition, vanadate enhances insulin receptor kinase activation (Fantus et al., 1994) 
and phosphorylation of a cytosolic, non-insulin tyrosine kinase linked receptor 
(Schechter et al., 1995) through inhibition of phosphotyrosine phosphatase. To 
determine whether changes in ET receptor regulation occur through tyrosine kinase 
mediated mechanisms, the effect of the tyrosine kinase inhibitor, genistein, on the 
observed ET receptor modulating effects o f  insulin and vanadate was determined. 
2.4.2.2.2. mRNA measurements 
If insulin and vanadate evoked changes in ET receptor binding characteristics, it was 
important to determine whether this effect was mediated at the gene level. Thus, 
subsequent to the binding studies, parallel experiments were carried out using 
northern blot analysis measuring ETA and ETB receptor mRNA expression in 
ASMC afier various time periods of preincubation with these agents. In addition, 
further studies with genistein in this regard were performed to elucidate the 
importance of tyrosine kinase linked pathways in changes in ET receptor mRNA. 
Finally, the role of new protein synthesis and active transcription were investigated 
using cycloheximide and actinomycin-D, respectively. 
2.4.2.2.3. Inhacellular calcium ([ca*+li) measurements 
It was of interest to determine whether upregulated ET receptors evoked by insulin 
and vanadate were coupled to a functional cellular response to ET-1. Under the 
optimal conditions established in receptor binding studies, the effect of insulin and 
vanadate pretreatment on ET agonist evoked increases in [cazcli was measured in 
isolated rat ASMC using fbra-2 methodology. Changes in the [Ca*+Ii response to 
ET agonists would add potential functional significance to ET receptor upregulation 
induced by insulin and vanadate. 
Parallel experiments with AVP and Ang I1 were done where [Cazfli responses to 
these two agonists were measured after the same pretreatment period with insulin 
and vanadate. This assumed importance in elucidating whether the actions of insulin 
and vanadate are specific to ET- 1. To determine the ETB response, IRL- 1620, an 
ETB selective agonist, was used in place of ET-1 under the same conditions. in 
addition, BQ123 (ETA antagonist) and BQ788 (ETB antagonist) were added to the 
cell suspension before ET agonist challenge in hopes of further differentiating the 
ETA and ETB contributions to agonist evoked [ca2+li after insulin and vanadate 
treatment. 
2.4.2.3. Ex vivo studies 
2.4.2-3.1. Vascular reactivity 
I f  our in vitro results were indicative of altered responses to ET-I in vivo under 
treatment conditions, then ET-I evoked vasoconstrictor responses might be 
exaggerated in vascular tissue from insulin and vanadate treated rats. Thus, to 
examine the fimctional relevance of the observed in vitro effects of insulin and 
vanadate, aortic rings were harvested from both non-diabetic SD and diabetic STZ 
rats treated with either insulin or vanadate. Towards this goal, rats were 
continuously treated with insulin via subcutaneous mini-osmotic ifision pumps for 
a period of 14 days, or with vanadate in drinking water. We deduced that long-term 
maintenance of hyperinsulinemia with mini-osmotic pumps would more adequately 
mimic physiological h y p e ~ s u h e m i a  than most previous studies that use short-term 
(e.g. 3 hr) hyperinsulinemic clamps. After this period, we measured vasoconstrictor 
responses to ET-1 in aortic rings harvested from these rats. In order to determine 
whether changes in vascular responsiveness were selective to ET-I, we also 
measured responses to the a -adrenoceptor agonist, methoxamine. Finally, since 
endothelial damage often occurs in diabetic states, we also investigated responses to 
the endothelium dependent vasodilator, ACh. 
2.4.2.3.2. Plasma endothelin-1 
Insulin evoked increases in ET-1 production from human EC and cultured human 
VSMC has been well characterized (Fem et al., 1995; Anfossi et al., 1993). 
Recently, in vivo studies have determined that this relationship also holds true in 
human hyperinsulinemia (Wolpert et al., 1993; Haak et al., 1992; Piatti et al., 1996). 
Thus, in addition to effects on vascular reactivity, parallel measurements of plasma 
ET-1 were made in insulin and vanadate treated rats. In addition to changes in 
responsiveness to ET-1, changes in the release of the peptide might also contribute 
to vasculopathy . 
3. MATERIALS & METHODS 
3.1. Animals 
Six to nine-week old male SD rats were purchased from Charles River, Montreal, 
QC. They were housed in the animal facilities with due care under standardized 
conditions with a light-dark cycle of 12 hrs at a temperature of 220C. Rats were fed 
ad-libiturn with Purina Rat Chow and tap water (unless otherwise indicated). 
Depending on the experiment, rats were killed between 12 and IS  weeks of age. 
3.2. Chemicals and Reagents 
3.2.1. Radiolabeled substances 
The radiolabeled substances, [12SI] ET- 1 and [I2511 IRL- 1 620 (specific activity 2200 
Ci/mmol) were from DuPont Canada (Mississauga, ON). The radioimmunoassay 
(RIA) kits for the measurement of plasma insulin and ET-1 were from Arnersham 
Life Sciences (Oakville, ON). 
3.2.2. Unlabeled peptides 
The unlabelled peptide-agonists ET- 1 (porcine/human) and IRL- 1620 [Suc- 
(glu9,~lal 1 1 5 )  ET- 1 1, as well as antagonists BQ 1 23 and BQ788 were purchased 
from American Peptide Co Inc. (Sunnyvale, CA). Angiotensin I1 (Ang 11) and 
arginine-vasopressin (AVP) were purchased from Sigma Chemical Co (St. Louis, 
MO). 
3m2A ETA and ETB cDNA probes 
Rat ETA and ETB cDNA probes were kindly provided as a gift from Dr. J. Winkles 
(American Red Cross, Rockville, MD) and Dr. P. Nambi (SmithKline Beecham 
Pharmaceuticals, King of Prussia, PA), and the p-actin probe from Dr. W. R. Roesler 
(University of Saskatchewan, Saskatoon, SK). 
3.2.4. Other substances 
Acetylcholine-chloride (ACh), a-actin, actinomycin D, arginine vasopressin (AVP), 
angiotensin I1 (Ang 11), bovine insulin, collagenase (Type IV), cycloheximide, 
DMSO, elastase (type IV), insulin (human), methoxamine hydrochloride, 
phenylephrine hydrochloride, sodium orthovanadate (vanadate), soybean trypsin 
inhibitor, streptozotocin (STZ), were purchased fiom Sigma Chemical Co (St. Louis, 
MO). Fura-2 AM and pluronic acid F-127 were from Molecular Probes Inc. 
(Eugene, OR). Dulbecco's modified essential medium (DMEM), new born calf 
serum, horse serum, penicillin, and streptomycin were from GIBCO BRL 
(Burlington, ON). Phosphate buffered saline (PBS), 1% Hank's balanced salt 
solution (HBSS), fungizone, 1-glutamine and trypsin were obtained from ICN 
Biornedicals Inc. (Costa Mesa, CA). Genistein was obtained fiom Calbiochem (La 
Jolla, CA). Mini-osmotic infusion pumps [model 20021 were fiom Alza Corporation 
(Palo Alto, CA). Iletin II insulin and sterile diluent were from Eli Lilly 
(Indianapolis, IN). All other chemicals were of analytical grade purchased from 
either BDH (Dartmouth, Nova Scotia, Canada), Calbiochem (La Jolla, CA), GIBCO 
BRL (Burlington, ON), or ICN Biomedicals Inc. (Costa Mesa, CA). 
3.3. Methods 
3.3.1. Cultured rat aortic smooth muscle cells 
33.l.l .  Isolation and culture 
Ten to twelve week old SD rats (1 50-200g) were used to isolate ASMC as described 
earlier (Gopalakrishnan et al., 1991). Before sacrifice, 3 or 4 rats were anesthetized 
by ether inhalation in a dessicator. Upon induction of anesthesia, rats were 
immediately killed by cervical dislocation and sterilized by immersion in 75% 
ethanol. All subsequent procedures of dissection, isolation and dispersion of ASMC 
were conducted under sterile condition (proviodine, 75% ethanol and heat were used 
for sterilizing surgical equipment). Aorta were carefully dissected out and cleared of 
fat and connective tissue by teasing with a teflon scraper. Aorta were then cut 
longitudinally and transferred to a plastic centrifuge tube containing 10 ml of Hank's 
balanced salt solution (HBSS) with 0.2% type IV collagenase, 0.1% type IV 
elastase, and 0.1 % soybean trypsin inhibitor. This solution was prefiltered through a 
0.2 pM filter to ensure sterility. The aorta in the digestion solution was incubated at 
37OC in a circulatory water bath set at 80 rpm for 5-10 min. The tissues were then 
transferred to fiesh HBSS and the vessels were cleaned fiuther (with relative ease) to 
remove the remaining adventitia, fat, and EC's surrounding the vessels. The cleaned 
vessels were then cut into 1-2 mm pieces and digested in the fiesh HBSS enzyme 
solution for a period of 40 min (80 rpm, 370C). At the end of this incubation, the 
digestion solution was discarded and the remaining tissue was rinsed 3 times with 
culture medium [20 mI of DMEM containing 10% heat inactivated newborn calf 
serum, 10% heat inactivated horse serum, 100 Ulml penicillin, 100 pg/ml 
streptomycin, 10 pg/ml fhgizone, 5.5. rnM glucose, and L-glutamine 2mM]. The 
tissue was then resuspended in fresh culture medium and triturated (40-60 times) 
with a sterile plastic transfer pipette until a single cell suspension was obtained. This 
suspension was then transferred to a sterile 75 mm* culture flask and kept at 37OC in 
a humidified 5% C 0 2  / 95% O2 atmosphere. After the cells adhered sufficiently to 
the bottom of the flask (3-4 days), the cell and tissue debris was removed and 
replaced with fiesh culture medium. 
3.3.1.2. Passage and maintenance 
Confluent monolayers formed between 6 and 8 days after isolation. This was 
referred to as the primary culture. When confluent, the culture medium was 
removed and the cells were treated with 0.06% trypsin in DMEM for 2-3 min at 
37OC until the cells started to show signs of detaching. This stage was identified 
morphologically under the microscope as when the spindle shaped attached cells 
became rounded. Trypsin was then quickly removed and the cells washed once with 
DMEM. Fresh culture medium was then added to the flask and the cells were 
detached by scraping with a teflon scraper and resuspended by trituration using a 
transfer pipette. The cells were then replated (in culture medium) at a split ratio of 
between 1 :3 and 1 :5 in either 24 well plates (-5 x lo4 cells/well; for receptor 
binding studies) or 75 cm* culture flasks (for [Ca*+Ii and ETA and ETB mRNA 
studies). The culture medium was changed every 2-3 days (throughout the period of 
maintenance of ASMC) and the cells multiplied to reach confluency in 3-5 days for 
each passage level. Sub-cultured cells were used between the 2nd and srn passage 
level. We have previously ascertained that ET-I binding characteristics as well as 
[cazcIi responses to ET-I were not significantly different between cells in primary 
culture and those maintained up to the fifth passage. Smooth muscle morphology 
was routinely assessed by microscope, and the level of contamination by fibroblasts 
was < 3% of the total population of cells. Moreover, occasional verification studies 
confirmed that >90% of cells showed positive immunoflourescent staining with a- 
actin antibody, confirming smooth muscle characteristics of adherent cells. Cell 
viability was routinely checked prior to experiments by trypan blue exclusion 
criteria. Dead or dying cells took up the blue dye while viable cells remained intact. 
Cell number was counted using a hemocytometer, Fisher counter and microscope. 
After ASMC attained confluency, the culture medium was removed and replaced 
with serum- free DMEM containing insulin and vanadate under various conditions. 
3.3.2. [lzsl] ET-I and [125~]  IRL-1620 receptor binding studies 
3.3.2.1. Treatment protocols 
The optimal concentrations and duration of incubation with insulin and vanadate that 
elicited maximal changes in [1*5I] ET-1 binding were first assessed. These were 
determined to be 100 nM for insulin and 25 p M  for vanadate, and both after 24 hr 
incubation. These optimal concentrations and time periods were subsequently 
utilized for detailed characterization studies. In order to determine whether tyrosine 
kinase activation was required for the observed effects of insulin and vanadate on 
[*251] ET-1 binding, the compounds were co-incubated with genistein (10 pg/ml), a 
well known tyrosine kinase inhibitor. Finally, in order to Mly characterize the 
effects of insulin and vanadate on subtypes of ET receptors recruited, saturation- 
binding studies were carried out. Such saturation studies enabled determination of 
the total population of ETA and ETB specific binding sites labeled by [1*5I] ET-1 
and ETB sites labeled by [I2511 IRL-1620 in the same population of cells for all of 
the groups under identical conditions. 
3.3.2.2. Receptor Binding Protocol 
All binding assays were conducted in duplicate. At the end of incubation with 
insulin or vanadate under the prescribed conditions, confluent ASMC were carefully 
washed twice at room temperature with 2 ml of binding assay buffer with the 
following composition: Tris-HCL 10 nM, 0.1% BSA, 10 pg/ml bacitracin in HBSS 
(pH 7.4). For concentration and time dependency as well as genistein studies, a total 
volume of 400 pL of binding assay buffer containing a fixed concentration of 20 pM 
[1251] ET-1 was then added to ASMC to the respective wells either in the presence 
or absence of unlabeled ET-1 (100 nM). For saturation studies, increasing 
concentrations of either [I2511 ET-1 or [I2511 IRL-1620 (2.5-150 pM; a minimum of 
8 concentrations for each group) were used rather than the fixed concentration of 
radioligand. Assays were always performed on the same day using the same group 
of control and insulin or control and vanadate pretreated cells. Radioligand was 
incubated with ASMC at 37OC for 2 hr, when equilibrium binding was reached. At 
the end of this incubation period, binding was terminated by aspirating the 
supernatant and washing twice with ice-cold HBSS. The cells in each well were 
then solubilized with 250 pl of 0.5% triton X-100 and transferred to a polystyrene 
tube (12 x 75 mm). Washings fiom the wells (2 x 250 pl of deionized, distilled 
water) were also added to the tube. Similar treatments were also applied to blank 
and total counts. Quantitation of radioactivity was measured by a gamma counter 
(Minaxi y Auto-Gamma 500 series, United Technologies, Packard, Downers Grove, 
IL). Cpm (counts per minute) values were converted to dpm (disintegrations per 
minute) values based on the calculated efficiency of the counter determined with 
each assay. Specific binding was obtained by subtracting non-specific binding fiom 
total binding. The non-specific binding was characterized as the residual binding of 
radioligand obtained in the presence of incubation with a high concentration of 
unlabeled ET- 1 (1 00 nM) maintained in parallel tubes. 
3.3.2.3. Analysis of binding data 
A combined computer program EBDA / LIGAND for the detection of single or 
multiple sites was used for analyses of the saturation binding data (McPherson, 
1985; Munson & Rodbard, 1980). Briefly, the cpm values obtained in duplicate 
fiom saturation binding experiments were converted into the respective dpm values 
using the formula: dpm = cpm 1 % efficiency. The following values for each 
concentration of radioligand were then fed into the program: total dpm values, non- 
specific binding, total dpm added to each well, specific activity (4,840,000 
dpdmole)  of radioligand and the volume of incubation medium (400 pl). The 
equilibrium dissociation constant (Ko), maximal binding capacity (B,,,J and Hill 
slope (nH) were obtained from Scatchard-plots. Since an estimate of number of cells 
could be determined by counting the total number of cells in three wells for each 
batch of assay, based on Avagadro's number, it was possible to express the 
estimated B,, values as the maximal number of binding siteslcell. 
3.3.3. Measurement of [Ca*+ji 
3.3.3.1. Treatment protocols 
Based on the optimal concentration and time of incubation conditions employed in 
the receptor binding studies, characterization of the [ca*+Ii responses to ET agonists 
and other peptides was then undertaken. The aim of these studies was to determine 
the functional relevance of the observed effects of insulin and vanadate on ET 
receptor expression. Firstly, afler a 24 hr incubation with either insulin (100 nM) or 
vanadate (25 pM), concentration-peak [ca*+Ji responses to ET-1 and IRL-1620 
were assessed in ASMC. Secondly, in order to determine the receptor subtypes 
recruited in the ET agonist evoked [ca*+li response under the treatment conditions, 
the effect of the antagonists BQ123 (ETA selective) and BQ788 (ETB selective) on 
ET-1 and IRL-1620 evoked responses was determined. Since insulin is also known 
to activate the IGF-1 receptor in high concentrations (King et al., l98O), the effect of 
IGF-1 on ET-1 evoked [Ca*+Ji responses was also determined. Finally, in order to 
assess whether the observed effects of insulin and vanadate were selective to ET- I,  
[ca*+Ji responses to the other peptide agonists, Ang I1 and AVP were examined after 
pre-incubation with these compounds. 
33.3.2. Preparation of cell suspension and Fura-2 loading 
After the prescribed treatments, confluent adherent ASMC maintained in 75 cm2 
flasks in serum free DMEM were trypsinized for 2-3 minutes and allowed to detach 
(as before). After washing twice with Krebs-HEPES buffer (1 45.0 mM NaCL, 5.0 
mM KCI, 1.8 mM CaC12-2H20, 1.2 mM MgC12.6H20, 10.0 rnM glucose, 10.0 nM 
HEPES, and 0.2 % BSA pH 7.4), ASMC were detached from the flask with a teflon 
scraper and dispersed in the same buffer using a transfer pipette. The ASMC 
suspension was then transferred to a polypropylene tube. In the meantime, a stock 
solution of 1 m M  acetoxymethyl ester of Fura-2 (Fura-2 AM) was prepared in 
dimethylsulfoxide (DMSO). 0.02% pluronic acid F-127 was added to h a - 2  AM 
solution to enhance loading efficiency. An appropriate volume of this stock was 
added to the cell suspension (approximately 0.5 x 106 cells/ml) to give a tinal 
concentration of 5 pM fbra-2 AM. The ASMC suspension with h a - 2  AM was then 
incubated at 37 O C  with a stirring speed of 120 rpm for 40 minutes. The suspension 
was subsequently subjected to centrifugation at 1100 g x 6 minutes at 4 O C  and the 
pellet obtained was twice washed by resuspending with KREBS buffer, followed by 
trituration and centrifbgation. This ensured removal of excess and unloaded dye. 
Afier the final wash, the cell pellet was resuspended in fresh buffer and diluted to 
achieve a concentration of - 1.5 x 106 cells/ml. The procedure for fura-2 AM 
loading has been described elsewhere (Gopalakrishnan et al., 1991 ; Sandirasegarane 
& Goplakrishnan, 1 995 ; Sandirasegarane et al., 1 994). Try pan blue exclusion test 
was used at this stage and also toward the end of the experiment (which takes 1-2 hr) 
to ensure that cell viability remained > 90%. Fura-2 loaded ASMC suspensions 
were kept on ice in light-restricted flasks to ensure that viability remained high and 
that fura-2 did not become quenched. 
3.33.3. Measurement of furs-2 fluorescence ratio 
For each determination, 500 p1 of f in-2 loaded ASMC suspension (0.15 x 106 cells) 
was added to the cuvette and maintained at 24 O C  with a stimng speed of 800 rpm. 
The basal as well as agonist evoked changes in the h a - 2  flourescence ratio were 
subsequently monitored by recording the signals R340/R380 in a JASCO 
spectroflourometer, CAF- 100 CaZC analyzer (Japan Spectroscopic, Tokyo). The cell 
suspension was challenged with agonist just once in order to avoid receptor 
desensitization, which is possible with repetitive additions of the agonist to the same 
cell suspension. Also, fura-2 leakage was minimal when the temperature was 
maintained at 250C throughout the experiment. Fura-2 is excited at 2 different 
wavelengths (340 and 380 nm) with an emission fluorescence of 500 nm. Free h a -  
2 maximally excites at 380 nrn, whereas the CaZC bound form is maximally excited 
at the lower waveIength (340 nm). Thus, the 340/380 fluorescence ratio is a 
measure of h a - 2  chelation to ~ a 2 + ,  which is directly proportional to the rise in the 
levels of free Cazf. Since intracellular fiee fura-2 is essentially trapped in the 
cytosolic compartment and is available to chelate ~ a * +  only in this compartment, 
free Ca2+ can therefore be considered cytosolic fiee Ca2+, or [ca2+li. The basal 
[Ca2+Ii values and the maximal increase in response to the addition of each 
concentration of agonist (peak [Ca**Ii values) were calculated from the respective 
flourescence ratio R according to the formula suggested by Grynkiewicz et al. 
(1985): [Ca2+Ji = kD x (R-Rmin)/(Rm,-R) x Sf2/Sb2. KD (224 nM) is the 
dissociation constant of fura-2 for Ca2+, R is the ratio of relative flourescence 
intensities (340/380) observed in mode I1 of the CAF-100 Ca2+ analyzer, Sb2 and 
Sf2 are the flourescence efficiencies of ~ a 2 +  bound and Ca*+ free fura-2, 
respectively, excited at 380 nm in mode 111. R,, and Rmin represent the maximal 
and minimal ratio of flourescence intensities respectively. The determinations of 
firstly Rmm and Sb2 values were performed by the addition of 40 pI of 10% Triton 
X-LOO to lyse the cells and expose the dye to the buffer concentration of ca2+ (1.8 
mM) which chelates to fura-2. Rmin and Sf2 were determined by subsequent 
addition of 20 p1 of 150 mM EGTA solution containing 450 mM Tris, pH 8.5 to 
achieve a final concentration of 6mM EGTA. 
3.3a4.4. Northern blot ETA and ETB mRNA measurements 
3.3.4.1. Treatment protocol and optimization 
In order to determine whether changes in ET receptor binding evoked by insulin and 
vanadate were due to changes in receptor expression, ETA and ETB mRNA 
measurements were undertaken using northern blot methodology. Firstly, using the 
optimal concentrations identified in concentration-dependency receptor binding 
studies, time-dependency studies were undertaken. Secondly, in order to determine 
whether tyrosine kinase activation was required for changes in ET receptor 
expression, insulin and vanadate treated ASMC were co-incubated with genistein 
(10 pg/ml) prior to mRNA studies. Finally, to determine whether new protein 
synthesis and active translation were required for the effects of insulin and vanadate, 
ASMC were co-incubated with either cycloheximide (10 pg/ml) or actinomycin-D 
( 1.5 pg/ml) prior to mRNA measurements. 
3.3.4.2. Total RNA isolation 
After the prescribed treatments, total RNA was isolated fiom confluent ASMC as 
previously described (Chomzynski & Sacchi, 1987). Serum-free DMEM was 
removed from the culture flasks and a denaturing solution was immediately applied 
(RNA STATdO). Lysed ASMC were then homogenized on ice with a polytron 
using three, 15 second bursts. One-fifth volume of chloroform was then added in, 
vortexed, and kept on ice for 15 min. It was then centrihged (10,000g 15 min, 
40C). The upper phase containing the RNA was carehlly removed and RNA was 
precipitated out by the addition of an equal volume of isopropanol, and kept at 
-200C overnight. The next day, the sample was again centrifuged at 10,000 g x 15 
min at 40C. The supernatant was removed and the sample washed twice. Washing 
entailed resuspending the pellet in 75% ethanol water followed by recentrifugation. 
AAer the second wash, the pellet was completely dried of ethanol then resuspended 
in Proteinase K buffer [0.1 M Tris (pH 7.5, 0.5 M NaCl, 1% SDS, 0.01 M EDTA 
(pH 73, 0.1 mg/ml Proteinase K] and incubated at 37 OC for 30 min. 
PhenoVchloroform/isoamyl alcohol (0.5 ml; 25:24: 1) was then added, vortexed, and 
centrifuged (10,000 g for 5 min). Aqueous layer was added to an equal volume of 
chloroform, mixed, then centrifuged again. Finally, the aqueous phase was again 
removed and mixed with 2 volumes of 75% ethanol and 1/10 volume of 3M 
NaAcetate (pH 5.2) and stored at -20 OC until the quantitation procedures. Before 
the subsequent procedures, the tubes were centrifuged (10.000 x g for 5 min) then 
washed once with 75% ethanol (as before) and finally suspended in DEPC .H20. 
3.3.4.3. Quantitation of isolated total RNA 
The amount and purity of RNA was measured by spectrophotometer. The 
concentration of RNA in solution was calculated based on an optical density of 1.0 
being equal to 40 pg/ml RNA. The purity was assessed as the ratio of fluorescence 
at 260 n M  to that at 280 nM. 
3.3.4.4. RNA electrophoresis 
Isolated total RNA was electrophoresed using the protocol developed by Pefle and 
Murphy (1993). RNA samples (20 - 30 pgAane) and molecular weight standards 
were first combined with loading buffer (0.25% bromophenol blue, 0.25% xylene 
cyanol, 30% glycerol, 1.2% SDS, 60 mM sodium phosphate, pH 6.8). The mixture 
was incubated for 5 min at 650C to denature the RNA secondary structure followed 
by rapid transfer to ice. The sample was then loaded onto 1.2% agarose gel 
dissolved in 10 mM sodium phosphate (pH 6.8), with 0.1 Wrn l  ethidiurn bromide. 
A charge of 5.5 V/cm of gel was applied allowing the RNA to traverse the gel. The 
gel was then visualized under U .V. light and photographed. 
33.4.5. Transfer of RNA to nylon membrane 
The standard blotting capillary elution technique adapted fiom Sambrook et al. 
(1989) was used to transfer the separated RNA to nylon membranes for funher 
analysis. The gel was first rinsed in 10 x SSC (3 M NaCl, 300 mM sodium citrate- 
trisodiurn salt, pH 7.0). The RNA was then transferred fiom the gel to the 
membrane using a capillary action apparatus with 10 x SSC for 12 - 18 hr. After 
transfer, the membrane was covered with plastic wrap and fixed to the membrane 
using a U.V. Stratalinker (1,200 joules). 
3.3.4.6. Preparation of probes 
3.3.4.6.1. Bacterial transformation 
100 ng of plasmid DNA containing either rat ETA or ETB cDNA fragments was 
added to 200 pl of competent E.Coli and DH5, respectively, mixed and stored on ice 
for 30 min. The mixture was then incubated at 42OC for 90 seconds and then rapidly 
chilled on ice for 1-2 min. 800 pl of LB medium (1% bacto-tryptone, 0.5% bacto- 
yeast extract, 1% NaCl, pH 7.0) was then added to each mixture. The competent 
cells were then incubated for 45 min at 37 OC to recover and express the antibiotic 
resistance marker encoded by the plasmid. The appropriate volume of transformed 
bacterial cells was spread over the surface of agar LB medium on 1.5% agar with 50 
pg/ml tetracycline. The plates were incubated overnight at 370C in an inverse 
position (Sambrook et al., 1989). 
3.3.4.6.2. SmaU-%ale preparation of plasmid DNA 
The procedure for both large and small-scale isolation of plasmid DNA was adapted 
from an earlier methodology (Sarnbrook et al., 1989). Different colonies picked up 
from each plate were cultured overnight at 370C with vigorous shaking in 2 ml LB 
medium with 50 pg/ml tetracycline. 1.5 ml of the culture was then centrifuged at 
12,000 g for 30 sec at 4 OC. The cell pellet was resuspended in 350 ml of STET [O. 1 
M NaCl, 10 m M  Tris.Cl (pH 8.0), 1 mM EDTA (pH 8.0), 5% triton X-1001 
containing 25 ml of fieshly made lysozyme (1 0 m g h l  in 1 0 nM Tris.Cl, pH 8.0) and 
vortexed. The sample was then immersed in boiling water for 40 seconds and then 
centrifirged ( 1 2,000 g x 1 0 min, room temperature). The pellet was removed with a 
toothpick before the addition of 40 p1 of 2.5 M sodium acetate (pH 5.2) and 420 pl 
of isopropanol. The mixed sample was kept for 5 min at room temperature before 
centrifugation (12,000 g x 5 min, 40C). The pellet was washed with 70% ethanol 
and dried at room temperature. The isolated DNA was dissolved in TE [lo mM 
Tris.Cl (pH 8.0), 1 rnM EDTA (pH 8.0)] and stored at -20 OC. 
3.3.4.6.3. Large-Scale preparation of plasmid DNA 
A large amount of cultured bacterial cells were collected by centrihgation at 4,000 g 
x 10 min and resuspended in 50 m M  glucose, 25 mM Tris.Cl (pH 8.0), 10 mM 
EDTA (pH 8.0) containing 1 mg/ml freshly made lysozyme, and then kept for 5 min 
at room temperature. After addition of 2 volumes of 0.2 N NaOH with 1% SDS, the 
sample was left at room temperature for 10 min. 1/3 volume of 5 M potassium 
acetate was then added and the sample was kept on ice for 10 min. The bacterial 
debris was subsequently removed by centrifugation (12,000 g x 20 min) and rinsed 
with 70% ethanol. The dried DNA was dissolved in TE (pH 8.0) with 20 pg/ml 
RNA'se and kept at room temperature for 30 min. The DNA soIution was extracted 
with an equal volume of phenol/chloroform (1 : 1 ratio) buffered with 0.1 M Tris.Cl 
(pH 8.0). The aqueous phase was separated by centrifugation and precipitated with 
2 volumes of ethanol at 4OC. After being maintained at room temperature for 
several min, the DNA pellet was obtained by centrifugation, rinsed with 70% 
ethanol, and dissolved in TE buffer (pH 8.0). 
3.3.4.6.4. Gel electrophoresis of  DNA 
Plasmid DNA and molecular weight marker were mixed with 115 volume of 6 x gel- 
loading buffer (0.25% bromophenol blue, 40% sucrose) before loading onto 1.2% 
agarose gels [dissolved in 1 x TAE (0.04 M Tris-acetate, 0.001 M EDTA, pH 8.0) 
containing 0.5 p g h l  ethidium bromide. A voltage of 1-5 V/cm was applied and the 
gel was run in 1 x TAE until the dye migrated to the appropriate position. 
33.4.6.5. Recovery of DNA fragments 
Plasmid DNA digested with restriction enzymes was separated by 1.2%, low melting 
point, agarose gel at 40C according to the protocol in the preceding section. Bands 
of cDNA fragments of ETA and ETB receptors were cut under the long-wavelength 
U.V. lamp. 5 volumes of 20 mM Tris.Cl, 1 mM EDTA (pH 8.0) was added to the 
slice of agarose. The gel was incubated for 5 min at 65OC. Before the gel was 
melted, it was cooled to room temperature before the addition of an equal volume of 
phenol, equilibrated to pH 8.0 with 0.1 M Tris.HC1. The sample was subjected to 
vigorous vortexing and then centrifuged at 4,000 g for 10 min at 200C. The aqueous 
phase was re-extracted once with phenoVchloroform and once with chloroform, and 
precipitated with 0.2 volume of 10 M ammonium acetate and 2 volumes of ethanol 
at 40C. After storage at room temperature, the DNA was recovered by 
centrifugation and rinsed with 70% ethanol. The dried DNA was dissolved in TE 
(pH 8.0) and the concentration measured by spectrophotometer following the 
procedure described earlier. An optical density of 1.0 corresponds to 50 pg/ml 
double stranded DNA. 
3.3.4.6.6. Radiolabeling of DNA 
Labeled nucleotides were incorporated in DNA synthesized by an oligo-labeling 
method (Feinberg & Vogelstein, 1983). The Prime-It-I1 random primer kit 
(Stratagene) was used. About 25-50 ng of cDNA fragment was heated in boiling 
water for about 2 min and then chilled on ice. 10 p1 of labeling 5 x buffer [l M 
HEPES (pH 6.6). 250 m M  Tris.HC1 (pH 8.0), 25 mM MgCl2, 10 mM DTT, 26A 
260 dm1 random hexadeoxyribonucleotides], 2 p1 of unlabeled dNTP's mixture 
(500 p M  dATP, 500 pM dGTP, 500 pM dTTP), 50 pCi [a -32P]  dCTP (3,000 
CUmmol, 10 pCi/pl) and 5 units of Klenow fragment of E.Coli DNA polymerase 1 
were then combined and adjusted to a total volume of 50 pl  with water. After 
incubation for 60 rnin at room temperature, the reaction was terminated by 5 pl 0.2 
M EDTA (pH 8.0). The radiolabeled probe was then separated from the 
incorporated dCTP through a Sephadex G-50 column. 
33.4.7. Northern hybridization 
The hybridization was performed using a QuikHyb (Stratagene) solution. A 
minimum of 33 p1 of QuikHyb/cm* of blot was used during both prehybridization 
and hybridization procedures. The membrane was first prehybridized for 20 min at 
680C. 100 p1 of 10 mg/ml salmon sperm DNA was added to the labeled probe (2.5 
x 106 counts/2 ml hybridization solution) and boiled for 2 min followed by chilling 
on ice. The mixture was then added to the prehybridization solution and 
hybridization was done for 1 hr at 68%. The membrane was then washed twice for 
15 min with 6 x SSC with 0.1% SDS, twice with 2 x SSC, and then once with 0.2 x 
SSC for 5 min at 600C. Autoradiography was done by first placing the membrane 
wrapped in plastic wrap in an exposing cassette overnight followed by visualizing 
and quantification using a PllosphorImager (Molecular Dynamics). 
3.3.5. Ex vivo studies 
3.5.5.1. Animals and treatment 
Nine-week old SD rats (1 50-200g) were fasted for 24 hr before being given either a 
single dose of STZ (diabetic group) (55 mglkg) in citrate buffer (pH 4.5) or citrate 
buffer alone (SD, non-diabetic group) via intraperitoneal injection. Hyperglycemia 
(>I5 m o M )  was confirmed in the treated rats after 1 week. At 3 weeks after STZ 
treatment, rats were divided into 8 groups of 8 rats each: SD-insulin control, SD- 
insulin treated, STZ-insulin control, STZ-insulin treated, SD-vanadate control, SD- 
vanadate treated, STZ-vanadate control, STZ-vanadate treated. Insulin treated rats 
received Iletin 11 insulin (Eli Lilly, Indianapolis, Indiana, USA) via subcutaneous 
miniosmotic pump (ALZA Corp., USA) diluted with sterile diluent (Eli Lilly, 
Canada) to allow for a delivery rate of 12 mU/Kg/min for 2 weeks. Iletin I1 insulin 
is pork-derived regular insulin with just a 2 amino acid difference from human 
insulin. Iletin I1 is has previously been used in STZ diabetic rats and is detectable 
with the rat insulin RIA kit. The insulin pumps were inserted into rats under sodium 
pentobarbital anaesthesia (SO mg/kg i.p.). Insulin controls received sterile diluent 
only by the same delivery method. Vanadate treated rats received 0.5 m g h l  sodium 
orthovanadate (vanadate) in drinking water freshly prepared every second day for 2 
weeks. Vanadate solution was buffered to pH 7.0 with ascorbic acid, as this has 
been suggested to decrease the toxicity of vanadate (Paulson et al., 1987). Vanadate 
doses were gradually increased over the week preceding the study to allow the rats 
to become accustomed to its inclusion in the water. Vanadate control rats were 
given tap water only. During the treatment period, all animals were housed in 
animal quarters with a 24 hr light-dark cycle and were fed standard rat chow ad 
libitum. Animals were weighed prior to and after treatment and food and water 
intake was monitored daily. Vanadate doses were gradually increased over the week 
preceding the study. 
3.3.5.2. Metabolic variables 
33.5.2.1 Blood and plasma sample collection 
At the end of the 2-week treatment period, animals were killed by decapitation under 
ether anesthesia. Blood samples were subsequently collected from the decapitated 
animals in tubes containing EDTA. 5 rnl of combined arterial and venous blood was 
easily obtained by this method. These were then centrifuged at 2000 g x 10 minutes 
at 4OC. Two aliquots of the supernatant plasma was subsequently obtained (200 pl 
and 1 ml) and stored at -70 OC until plasma insulin and ET-1 measurements were 
undertaken. A drop of blood was also obtained from the decapitated animal at the 
time of sacrifice upon which plasma glucose was measured. 
3.3.5.2.2. Plasma glucose measurements 
Plasma glucose in the drop of blood was measured by a glucose oxidase method 
incorporated into an easy to use, hand-held blood glucose analyzer (One Touch 
Basic, Lifescan, Vancouver, BC). With this system, blood glucose levels were 
recorded accurately within 45 seconds. 
3.3.5.2.3. Plasma insulin measurements 
Plasma insulin concentrations were measured in the frozen 100 pl aliquots using a 
commercially available RIA kit (Amersham, Oakville, ON, Canada). The assay is 
based on the competition between unlabeled insulin and a fixed quantity of [1251]- 
labeled human insulin for a limited number of binding sites on an insulin antibody. 
Using fixed amounts of antibody and radioactive ligand, the amount of radioactive 
ligand bound by the antibody is inversely proportional to the concentration of added 
non-radioactive ligand. Firstly, all reagents (standard, antiserum, and [ I  2 s ~ ]  insulin 
radiotracer) were diluted with assay buffer (0.052 M phosphate buffer pH 7.5 
containing 0.1% sodium azide). Both the antiserum and radiotracer were then 
combined with the insulin samples and standards, vortexed and allowed to incubate 
for 4 hr at room temperature. After this, the Amerlex-M second antibody reagent 
(which contains second antibody that is bound to polymer particles) was added to the 
antibody bound insulin, vortexed and allowed to incubate at room temperature for a 
fivther 10 min. Separation of the antibody bound fraction was then effected by 
centrifugation (1500 g x 10 min; 30C) followed by decantation of the supernatant by 
inversion of the tubes in decantation racks and allowing to drain for 5 min. 
Radioactivity in the pellet from each sample was then counted for a period of 60 
seconds in a gamma-counter. This enabled the amount of labeled insulin in the 
bound fraction to be calculated. Briefly, non-specific binding was first subtracted 
from all counts. The percent bound divided by zero standard was then calculated for 
each standard and sample and plotted against insulin concentration on a standard 
curve. The concentration of unlabeled insulin in the sample was then determined by 
interpolation fiom this standard curve. Further relevant information provided by the 
manufacturer is as follows: The assay was completely cross-reactive with insulin 
fiom a variety of species including rat and human. The sensitivity was 48 pg/ml, 
within-assay and between-assay precision was determined to be 5 and 13 % 
respectively, and recovery was between 1 10 and 1 1 7%. 
3.3.5.3. Plasma endothelin measurements 
Plasma ET-1 concentrations were also measured in frozen 1 ml plasma aliquots. 
Sample preparation was first completed by acidifying the plasma sample with 2 M 
HCl and centrifuging at 1000 x g for 5 min. The sample was then loaded onto 
Amprep 500 mg C2 mini-columns (Amersham), washed with 0.1% trifluoroacetic 
acid (TFA), and then eluted with 80% acetonitrile and 0.1 % TFA. The sample was 
then dried down under nitrogen and resuspended in assay buffer (20 mM sodium 
borate, 0.1 % BSA, 0.1 % tween 80, and 0.1 % sodium azide). ET- I levels in the 
samples were then measured using a commercially available RIA kit (Amersham, 
Oakville, ON, Canada). The assay is based on the competition between unlabeled 
ET-1 and a fixed quantity of [l*sI]-labeled ET-3 for a limited number of binding 
sites on an ET 1-21 specific antibody. Similar to the insulin RIA, the amount of 
radioactive ligand bound by the antibody is inversely proportional to the 
concentration of added non-radioactive ligand. Briefly, all reagents (standard, 
antiserum, radiotracer) are first reconstituted with assay buffer. Antiserum is then 
added to the sample and standards, vortexed and allowed to incubate for 4 hr at room 
temperature. [125I]-ET-3 (radiotracer) is then added to the tubes, vortexed and 
allowed to incubate for 16-24 hr at 2-PC. The Amerlex-M second antibody reagent 
is then added, vortexed and allowed to incubate for a further 10 min at room 
temperature. Separation of the antibody bound fraction is then achieved by 
centrifugation (1500 g x 10 min, 40C) followed by decantation. Radioactivity is 
then counted in a gamma-counter and ET-1 levels are subsequently determined in 
the same manner as with the insulin RIA. Cross reactivity of the kit was negligible 
with other unrelated vasoactive peptides as well as big-ET-1. However, cross 
reactivity was complete to other ET isopeptides including ET-2, ET-3, S6c, and 
vasoactive intestinal contractor. Recovery of ET- 1 was determined to be 79%, 
sensitivity of the assay is 0.2 pmoV1, and within-assay and between-assay precision 
was 396% and 9-1 7% respectively. 
3.3.5.4. Ex vivo vascular reactivity studies 
3.3.5.4.1. Isolation and preparation of aortic rings 
Immediately after the rats were sacrificed, the thoracic aorta was dissected fiom each 
rat and transferred to a petri-dish containing modified Kreb's physiological salt 
solution (NaCl 1 18 mM, KC1 4.7 rnM, KH2PO4 1.2 mM, MgC12-6H20 1.2 mM, 
CaC12-2H20 1.8 mM, NaHCOj 25.0 rnM, and glucose 1 1.1 mM) continuously 
oxygenated with 95% 02/5 % C02 at 370C. It was then cleared of adhering fat and 
connective tissue using dissecting scissors and gentle teasing and subsequently cut 
into 5 rnm ring segments. For experiments requiring endothelium denudation, the 
ring segment was gently rubbed between the thumb and forefinger. Denudation was 
verified by a lack of vasodilatory responses to ACh. Using this method, complete 
fimctional denudation of the endothelium was achievable with minimal effects on 
underlying VSM function. The rings were then suspended on ring supports in 10 rnl 
organ baths containing modified Kreb's buffer continuously oxygenated with 95% 
0 2 / 5  % C 0 2  at 37 OC. One end of the ring support was anchored to the base of the 
bath while the other was attached to an FT0.3 isometric force transducer connected 
to a Grass 7E polygraph. Baseline isometric tension was subsequently set at 2 g by 
adjusting the vertical level of the transducer apparatus. 2 g was chosen as baseline 
tension since this was the level at which force development to a maximal 
concentration of ET- 1 (1 00 nM) was optimal. 
3.3.5.4.2. Analysis of agonist evoked responses 
The aortic segments suspended in the organ bath were allowed to equilibrate for 1 hr 
(with changes of the buffer every 20 min) before the tissue was precontracted with a 
single concentration of phenylephrine (30 pM) to stabilize the preparation. After the 
level of tension returned to basal levels (after - 15 minutes), agonist challenges were 
undertaken. The agonists were added in 50-100 p1 quantities so as not to increase 
the required fmal bath concentrations. In one set of rings, ET-1 (1 00 pM - 100 nM) 
was added in a cumulative dose fashion in order to elicit a concentration-dependent 
vasoconstrictor response. In a separate set of rings, similar responses to 
methoxamine (100 nmollL - 100 pmol/L) were assessed. At the peak of 
methoxamine evoked contraction in these rings, cumulative dose relaxations to ACh 
(100 nmoVl - 100 pmol/l) were then undertaken. At the end of each experiment, 
tissues were allowed to dry overnight, weighed, and the cross sectional areas were 
calculated to allow for expression of tension development in g/mm2. This method of 
representing tension-response data is advantageous in that it controls for differing 
amounts of smooth muscle in the vessel wall (Wyse, 1980). 
3.3.6. Statistical analysis 
The ECso values for agonist induced increases in peak [ca2+li levels and tension 
responses were derived from log concentration-response curves. All results were 
expressed as mean & SEM. The comparison of data obtained for each group was 
subjected to analyses using ANOVA or student's t-test as appropriate. Simultaneous 
multiple comparisons were examined using Scheffe's F-test. 
4. RESULTS 
4.1. Aortic smooth muscle cells 
After initial isolation, the time required for ASMC to reach confluency in the flask 
varied fiom 6 to 8 days. ASMC were allowed to proliferate due to the presence of 
L-glutamine, horse serum, and newborn calf serum in the incubation medium. 
ASMC grew in a characteristic 'Hill and Valley' pattern, with the valleys 
representing the monolayer of cells. Individual ASMC are spindle shaped and they 
differ fiom fibroblasts in that they have only one or two nucleoli present in the 
nucleus while fibroblasts have four or five. Although cobble-shaped EC's are 
common contaminants of the culture, care was taken to ensure the meticulous 
removal of these cells during the initial isolation as well as during the period of 
initial growth before the cells attained confluency. Although ASMC could be more 
adequately characterized with the routine use of anti-actin or anti-myosin antibodies, 
the above procedure was used to obtain ASMC cultures with high purity. The 
efficacy of this technique was verified with occasional antibody studies. Viability of 
cells was repeatedly monitored using the trypan blue exclusion test, whereby dead or 
dying cells take up the blue dye, while healthy cells remain intact. Viability of cells 
was consistently greater than 90%. ASMC viewed under a microscope on both low 
and high power are shown in Figure 10. 

4.2. Effkcta of insulin and vanadate on endothelin receptor characteristics and 
endothelin agonist mediated elevations of [ca2+li 
4.2.1. [125~] ET-1 and [l*SI] IRL-1620 binding studies 
4.2.1.1. Concentration and time dependent increase in [1*5I] ET-I specific 
binding 
4.2.1.1.1. Insulin pretreated celb 
Pretreatment with insulin (0.1 - 1000 pM) for 24 hours led to a concentration 
dependent increase in [I2511 ET-1 (20 pM) specific binding (Figure 1 la). The 
minimum concentration of insulin needed to evoke a significant increase was 10 nM 
(144 + 10 %; p < 0.05). Peak effect occurred at 100 nM insulin which was 2-fold 
higher (207 + 14 %; p < 0.01) than specific binding in control cells. When ASMC 
were pretreated with a fixed concentration of insulin (100 nM) for varying time 
periods (6, 12, 18 and 24 hrs), a significant increase in [1*51] ET- 1 specific binding 
was evident by the 24 hr time point (Figure 1 lb). The maximal increase in specific 
binding at this point was 250 + 45% of control levels (p < 0.01). Incubation for 
longer time periods elicited no tirrther increases (30 hr time point; 21 1 + 20% of 
control levels; p < 0.01 ). Therefore, in subsequent detailed characterization studies, 
a concentration of 100 nM and a time interval of 24 hr were chosen as the optimal 
conditions. Insulin was not maintained in the assay medium during the measurement 
of ['*51] ET-1 specific binding. Pretreatment with insulin did not visibly affect cell 
morphology or viability (>90%). 
Insulin (nM) 
Time (hr) 
Figure 11. Concentration (a) and time (b) dependent increase in [l251] ET-1 specific 
binding to rat ASMC after insulin pretreatment. Adherent cultured rat ASMC (-2 x 
1 O5 cells/well) were incubated with increasing concentrations of insulin for different 
time periods. Each data point is a mean SEM of 5 separate experiments performed 
in duplicate. 
*p < 0.05; ** p < 0.01 vs. control group. 
4.2.1.1.2. Vanadate pretreated cells 
Pretreatment of rat ASMC with vanadate also led to a concentration and time 
dependent increase in specific binding of a fixed concentration of 20 pM [l*SI] ET- 
1. The maximal effect was observed with a concentration of 25 pM vanadate which 
was statistically significant @ < 0.0 1) and was two fold higher (206 * 16%) than the 
data from the control group of cells (Figure 12a). In time dependency experiments, 
a significant (p < 0.01) increase in ['ZSI] ET-1 specific binding was seen at 24 hr, 
and pretreatment with vanadate for longer durations (30 hr) did not result in hrther 
increases (Figure 12b). 
4.2.1.2. Effect of genistein on [l*SI] ET-1 specific binding in insulin and 
vanadate pretreated cells 
To examine the role of protein tyrosine kinase in vanadate and insulin evoked 
increases in ET-1 binding, ASMC were incubated in the presence of a low 
concentration of genistein (1 0 pM), a known tyrosine kinase inhibitor. Pretreatment 
with genistein per se for 24 hr did not affect the specific binding (99 + 9%) of a 
fixed concentration of 20 pM [I2511 ET-1 to ASMC (Figure 13). However, co- 
incubation of genistein with either insulin (100 nM) or vanadate (25 pM) for 24 hr 
abolished the increases in specific binding evoked by both compounds. 
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Figure 12. Vanadate evoked concentration (a) and time (b) dependent increases in 
ET- 1 specific binding to rat ASMC. 
*p < 0.05 and ** p < 0.01 vs. control group (n = 5). 
Figure 13. Effect of genistein on insulin and vanadate evoked increases in ET 
receptor binding. 
** p < 0.01 vs. control group (n = 5). 
4.2.13. Saturation analysis of [a2511 ET-I and [1*51] -1620 specific binding 
Saturation analysis of [129] ET- 1 and [12'1] IRL- 1620 was undertaken to detennine 
the maximal number of binding sites per cell (B,), and affinity constants (KD) for 
each radioligand. The specific binding was 99% of total binding at low 
concentrations of [1"1] ET- 1 and it decreased to 90% of total bound radioligand at 
saturating concentrations in the control ASMC. Moreover, bound radioligand 
amounted to 18 to 40% of the total ET-1 radioligand added to the medium. 
Interestingly, in insulin and vanadate pretreated cells, this effect was even more 
pronounced as the specific binding sites increased several fold and thus, the signal to 
noise ratio was much higher. Complete saturation of [I2511 ET-1 binding sites 
occurred at 300 pM. In contrast to [I2511 ET- I ,  the signal to noise ratio levels were 
relatively less in the case of [I2511 IRL 1620 (data not shown). 
Saturation binding data from single experiments for both [IzsI] ET-1 and [l*sI] IIU 
1620 performed on the same day using the same batch of cells under identical 
conditions are shown in figures 14 and 15 (for insulin groups), and Figures 17 and 
19 (for vanadate groups). Scatchard analysis is shown in Figures 16 (for insulin 
groups) and 18 and 20 (for vanadate groups). Monophasic plots with Hill coefficient 
(nH) values close to unity (between 0.90 and 1.00) were obtained for both 
radioligands. Vanadate pretreatment led to marked increases in B,, for both [I2511 
ET-1 and [I2511 IRL 1620 saturation with no significant changes in slope or KD 
values of the plots. Insulin pretreatment, however, led only to a significant increase 
in B,, for [I2511 ET-I, and a slight, but non-significant increase in that of 
I=- 1620. Moreover, with either radioligand, saturation data did not provide best fit 
for a two-site model. Summary data is presented in Table 1 (for insulin groups) and 
Table 2 (for vanadate groups). It is evident that [1*5I] IRL-1620 labeled relatively 
fewer sites (685 - 945 siteskell) denoting the existence of a small population of ETB 
specific sites (1 2- 14 % of the total sites labeled by [lZ51] ET- I) in the control groups. 
Based on the data obtained with both radioligands, it is evident that rat ASMC 
possess predominantly ETA sites (86-88%) with a very high ETA I ETB ratio of 6.05 
- 7.3. Pretreatment of ASMC with insulin led to a 2.06 fold increase @ < 0.01) in 
sites labeled by ["q] ET-1, but did not significantly affect [I2511 IRL-1620 labeled 
ETB sites, indicating selective upregulation of ETA specific binding sites. However, 
the overall, cell surface ETA /ETe ratio did not dramatically change (7.20 insulin vs. 
6.05 control) (Table 2). Insulin had no affect on KD values for either radioligand. 
Pretreatment with vanadate led to a 2.6 fold increase (p < 0.01) in the number of 
binding sites labeled by [I2511 ET-I (14740 + 2009) and a 7.8 fold increase (p < 
0.01) in [I2511 IRL 1620 (5356 + 393) labeled ETB sites. Since the recruitment of 
ETB specific sites was markedly higher, the overall, cell surface ETA/ETB ratio on 
ASMC was reduced from 7.3 to 1.8 by vanadate pretreatment. Pretreatment with 
vanadate also @ < 0.05) increased the KD value for ['2SI] ET-1 but not [I2511 IRL 
1620 binding likely due to a very highly significant shift in the B,, for ET-1. 
Figure 14. Saturation binding curves for [l*SI] ET-1 in either untreated (a) or insulin 
(b; 100 nM; 24 hr) treated ASMC (- 0.47 x 106 cells/well) under equilibrium 
conditions (370C for 3 hr) either in control or insulin (100 nM x 24 hr) pretreated 
ASMC. Note: Serum was deprived in DMEM medium 24 hr prior to initiating 
binding assays in both control and insulin pretreated cells; then the cells were 
washed in senun free DMEM thrice, and saturation binding studies were carried out 
in Krebs-HEPES buffer (pH 7.4). Increasing concentrations of [1*51] ET- 1 were 
added to ASMC in duplicate in the absence (total binding) or presence (non-specific 
binding) of unlabeled ET-1 (100 nM) for a period of 3 hr (370C). Non-specific 
binding was never greater than 3% of total binding. 
0 totalbinding 
V specific binding 
non-specific binding 
0 50 100 150 
0 50 100 150 
0 total binding 
V specific binding 
15007 non-specific binding 
Figure 15. Saturation binding c w e s  of [l*sI] IRL-1620 in either untreated (a) or 
insulin treated (b; 100 nM; 24 hr) ASMC. Increasing concentrations of [lZ51] IRL- 
1620 were added to ASMC in duplicate in the absence (total binding) or presence 
(non-specific binding) of unlabeled ET- 1 (1 00 nM). Non-specific binding was never 
greater than 10% of total binding. 
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Figure 16. Scatchard plots of representative experiments performed under identical 
conditions examining [I2511 ET-1 (a) and [125~] IRL-1620 (b) specific binding to 
insulin pretreated and control ASMC. 
TABLE 1 
Analyses of saturation of [1251] ET-1 and [I2511 IRL-1620 specific binding in either 
insulin pretreated or control untreated aortic smooth muscle cells. 
GROUP 
Control 
N=6 
Insulin 
100 nM - 24 hr 
n=6 
ET- 1 IRL- 1620 
* * p -= 0.0 1 compared to respective control B, values. 
Ratio 
Note: After incubation of rat ASMC with insulin (100 nM for 24 hr), the cells were 
washed with serum free medium prior to binding assays. 
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Figure 17. Saturation binding curves of [I2511 ET-1 in either untreated (a) or 
vanadate treated (b; 25 pM; 24 hr) ASMC. Increasing concentrations of [1*51] ET-1 
were added to ASMC in duplicate in the absence (total bindiig) or presence (non- 
specific binding) of unlabeled ET- 1 (1 00 nM) for a period of 3 hr (370C). 
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Figure 18. Scatchard plots of a representative experiment examining [1*5I] ET-1 
specific binding either in control or vanadate (25 @I x 24 hr) pretreated ASMC. 
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Figure 19. Saturation binding curves of ['251] IRL-1620 in either untreated (a) or 
vanadate treated (b; 25 pM; 24 hr) ASMC. Increasing concentrations of [1*5I] IRL- 
1620 were added to ASMC in duplicate in the absence (total binding) or presence 
(non-specific binding) of unlabeled ET-1 (1 00 nM). 
0 I I I 1 
0 2.5 5 7.5 10 
125 [ IIIRL- 1 620 Specific Bound (pM) 
Figure 20. Scatchard plots of a representative ETe binding assay examining [12SI] 
IRL-1620 specific binding to rat ASMC either in control (a) or vanadate (25 pM; 24 
hr) pretreated ASMC (b). 
TABLE 2 
Analyses of saturation of [I2511 ET- 1 and [I2511 IRL-1620 specific binding in either 
vanadate pretreated or control untreated aortic smooth muscle cells. 
ET- 1 
* p < 0.05 compared to control KD value for ET-1 
** p < 0.01 compared to respective control B,, values. 
ETA/ETB 
Ratio 
Note: Vanadate incubation (25 p M  for 24 hr) with rat ASMC was carried out in 
serum free DMEM; at the end of the incubation period, the cells were washed twice 
in serum free medium prior to initiating equilibrium binding assays. 
43.2. Measurement of  [Ca2+li in ASMC 
4.2.2.1. Effteet of insulin and vanadate om concentration-peak [ca2+li responses 
to ET-1 and IRL-1620 
Incubation with vanadate (25 pkf) or insulin (100 nM) for a period of 24 hr did not 
alter the morphological characteristics of the adherent ASMC prior to or after h a - 2  
loading. Dispersed cells from both treatment groups showed >90% viability prior to 
[ca2+li measurements. Representative data for ET-1 evoked changes in h a - 2  
fluorescence from a single experiment performed on the same day using similar 
loading conditions from the same batch of ASMC for both control and insulin 
(Figure 21) and control and vanadate (Figure 22) pretreated groups is shown. There 
were no significant differences in basal [ca2+li levels between either control (73 2 
12 nM) and vanadate (8 1 + 18 nM) or control (80 + 10 nM) and insulin (75 + 1 1 
nM) pretreated ASMC. ET-1 evoked a well-defined concentration dependent 
increase in the peak fura-2 fluorescence signal in all of controls, insulin, and 
vanadate pretreated groups. The peak [ca*+li response to ET-1 was reached within 
1 min and a steady state plateau phase was attained 3-4 min after agonist challenge 
in both control and insulin pretreated cells. The maximal response (ET-1 evoked 
peak [Ca2+li) achieved was much higher in the insulin and vanadate pretreatment 
groups compared to untreated controls. Figures 23a and 24a represent pooled data 
of several ET-1 concentration-peak [ca2+li response curves. At a maximal 
concentration of 100 nM ET- I ,  the maximal [CazcJi increase (E,) was 1.68 fold 
higher in the insulin (300 + 20 nM) treated group compared to its respective control 
group (1 79 + 16 nM) and 1.7 fold higher (1 47 + 1 3 nM; p < 0.0 1 ) in vanadate treated 
vs. its respective control group (87 15 nM). There were no significant differences 
in calculated ECSO values between control (2.1 + 0.4 nM) and vanadate (3 -3 & 0.6 
nM) and control (7.8 + 2.8 nM) and insulin treated (8.1 + 2.1 nM) ASMC. 
Pooled data for ETB mediated IRL-1620 evoked changes in [Ca2+Ii are shown in 
Figures 23b and 24b. Although IRL-1620 also evoked a concentration dependent 
increase in peak [Ca*+Ii levels, the responses were much lower. In fact, a shift from 
basal values was marked only at concentration ranges above 10 nM I IU-  1620. The 
maximal increase in [CaZfli attained at a maximal concentration of 200 nM IRL 
1620 was three-fold higher @ < 0.01) in vanadate treated cells (Emax 77 + 4 nM) 
compared to its untreated control group (Em, 26 + 7 nM). There were no 
significant differences in EC5* values between the two groups (vanadate: 8.5 + 2.1 
nM; control: 7.8 + 0.8 nM). In contrast, insulin pretreatment had no significant 
effect on maximal [ca2+Ii responses to IRL-1620 (control 3 1 + 6 nM; insulin 24 + 7 
nM) and again, there were no significant differences in ECSo values between control 
(6.0 + 3.3 nM) and insulin pretreated (7.1 + 4.2 nM) ASMC. 
Figure 21. Relationship between increasing concentrations of ET- 1 and 
corresponding increases in fum-2 fluorescence (ratio of 340:38O excitation of ha-2)  
in a fixed aliquot of dispersed ASMC (0.15 x 106 cells / 0.5 ml Kreb's-HEPES 
buffer pH 7.4) in control (a) and insulin (b) pretreated ASMC. Initially, adherent 
ASMC maintained in culture flasks were first washed and then maintained in serum 
free medium (control) or treated with insulin (100 nM). At the end of 24 h.,  ASMC 
were trypsinized, washed, and dispersed in Kreb's-HEPES buffer (pH 7.4). ASMC 
were loaded with h a - 2  AM (5 pM), washed, and a fixed aliquot of cell suspension 
was utilized to determine [Ca*+Ii levels. Each aliquot was challenged with one 
concentration of ET-1 and then discarded. The tracings were recorded for a period 
of 4 min after the addition of ET- 1 when a steady plateau phase had been reached. 

2 min. chart speed (12 mdmin)  
Figure 22. Representative conccneationdependent increase in [Ca2+Ji responses to 
ET- 1 in control (a) and vanadate pretrcated cells (b). 
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Figure 23. Relationship between concentration-peak [Ca*+Ii responses to ET-1 (a) 
and IRL- 1620 (b) in control and insulin pretreated ASMC. Each data point is a 
mean + SEM of six separate experiments using different batches of ASMC. 
*p c 0.05 and * p < 0.0 1 compared to the same data point for the control group. 
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Figure 24. Relationship between concentration-peak [CazfIi response curves to ET- 
1 (a) and IRL-1620 (b) in Vanadate pretreated (25 pM; 24 hr) and control ASMC. 
Each data point is a mean SEM of 4 separate experiments. 
*p < 0.05 and ** p < 0.01 compared to control group. 
4.2.2.2. Comparison of peak [ca*+li elevations to ET-1 and IRL-1620 in the 
presence and absence of endotbelin receptor subtype specific antagonists 
BQ123 and BQ788 
The inclusion of a high concentration of BQ-123 (1 @I), an ETA selective 
antagonist, to the ASMC suspension in the cuvette led to a significant @ < 0.01) 
abolition of [Ca2+li responses to a submaximal concentration of ET-1 (10 nM) in all 
of control, insulin, and vanadate pretreated cells (Figure 25 & 26). In the control 
group, the magnitude of blockade of ET-1 evoked [Ca2+Ii response was markedly 
higher in the presence of BQ-123, than in the presence of the ETB selective 
antagonist, BQ-788 (1 @I). In both insulin and vanadate pretreated ASMC, as 
demonstrated earlier, ET- 1 evoked [Ca*+Ji responses were exaggerated. In insulin 
pretreated ASMC, BQ-123 similarly blocked most of the increase in ET-1 evoked 
[Ca2+Ii, while BQ788 had much less effect, suggesting greater recruitment of ETA 
sites by insulin (Figure 25) - in line with the binding data. In contrast, in vanadate 
pretreated ASMC, both BQ-123 and BQ-788 abolished the increases in [Ca2+Ii 
responses to ET-1 to the same extent, suggesting enhanced recruitment of both ETA 
and ETB signaling (Figure 26). IRL-1620 evoked [ca2+li responses in all groups 
were unaffected by BQ-123 but the responses were almost completely abolished by 
BQ-788, verifying the subtype selectivity of each of these agents. As demonstrated 
earlier, insulin pretreatment had no significant effect on IRL- 1620 evoked [CazfJi 
responses, whereas vanadate pretreatment greatly enhanced it, again suggesting 
enhanced recruitment of ETB sites by vanadate. 
Figure 25. Effects of the ETA selective antagonist, BQ123, and the ETB selective 
antagonist, BQ788, on peak [caztIi responses to ET-1 and IRL-1620 in control and 
insulin (100 nM; 24 hr) pretreated ASMC. Data shown are pooled values of mean 2 
SEM of 6 separate experiments for the maximal increase in [Ca*+Ii above resting 
levels attained after the addition of a fixed concentration of either ET-1 (10 nM) or 
IRL- 1620 (1 0 nM) in both control and insulin pretreated ASMC. Subtype specific 
antagonists were incubated with ASMC for a period of 4 min prior to the addition of 
agonist (ET- I or IRL- 1620). 
*p < 0.05; **p < 0.01 vs. respective control group; + p < 0.05; ++ p < 0.01 vs. 
respective insulin pretreatment group. 
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Figure 26. Effects of BQ123 and BQ788 on peak [Ca*+Ii responses to ET-1 and 
IRL-1620 in control and vanadate (25 pM; 24 hr) pretreated ASMC. Data shown 
are pooled values of mean + SEM of 6 separate experiments for the maximal 
increase in [Ca2+Ji above basal levels. 
*p < 0.05; *+ p < 0.01 vs. respective control group; + p < 0.05; ++ p < 0.01 vs. 
respective vanadate pretreated group 
4.2.23. Comparison of peak [Ca *+Ii responses to vasopressin, angiotensin 11, 
and endothelin-1 
In order to determine whether increases in ET receptor expression and action are 
selective to ET-I, experiments were completed whereby incubation with insulin (1 0 
nM) and vanadate (20 @I) were tested for their ability to affect Ang I1 and AVP 
evoked [CazfJi responses. Since high concentrations of insulin are known to 
activate IGF- I receptors (King et a]., 1980), IGF- 1 (1 0 pg/ml) was also tested for its 
effects on ET-I, Ang 11, and AVP evoked [Ca2+Ii responses. The effect of insulin 
on agonist evoked [Ca*+li signaling was selective to ET- I, since [CazcJi responses 
to 100 nM Ang I1 and AVP were unchanged between control and insulin pretreated 
ASMC (Figure 27a). Similarly, IGF-1 selectively increased [ca2+li responses to 
ET-I, leaving Ang I1 and AVP evoked responses intact (Figure 27b). However, in 
addition to promoting a 2-fold increase in ET-I evoked [Ca2+li responses, 
surprisingly, vanadate actually dramatically attenuated Ang I1 evoked [CazcIi 
responses (Figure 27c). 
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Figure 27. Effect of 10 nM insulin (a), 10 pglrnl IGF-I (b), and 25 pM vanadate 
pretreatment on ET-I, Ang 11 and AVP (100 n M  each) evoked peak [Ca2+Ii 
responses in rat ASMC. Data represents mean + SEM of 4 separate determinations. 
* p < 0.0 1 vs. respective control. 
4.23. Measurement of ETA and ETB mRNA 
4.2.3.1. Time dependent changes in ETA and ETB mRNA expression evoked by 
insulin and vanadate 
To examine whether increases in cell surface ETA and ETB binding sites evoked by 
insulin or vanadate pretreatment were due to enhanced ET receptor mRNA 
expression, northern analysis of ETA and ETB mRNA levels were carried out. Time 
dependency of this effect is presented in Figures 28 and 29. While only ETA mRNA 
was upregulated in insulin (LOO nM) pretreated ASMC (Figure 28), both ETA and 
ETB mRNA levels were upregulated in vanadate (25 pM) pretreated cells (Figure 
29). These effects became apparent at 12 hours, and maximal at 20 hr. 
4.2.3.2. Effect of Genistein on insulin and vanadate evoked changes in ETA and 
ETB mRNA expression 
Incubation of ASMC with the tyrosine kinase inhibitor genistein (1 0 pM) per se for 
20 hr failed to evoke appreciable changes in ETA and ETB mRNA levels. However, 
elevated ETA mRNA levels evoked by insulin (Figure 30) and increased ETA and 
ETB mRNA levels evoked by vanadate (Figure 31) were abolished by inclusion of 
genistein in the incubation medium. These data indicate the requirement for tyrosine 
kinase activation in the effects of insulin and vanadate on ET receptor expression. 
4.233. Effect of actinomyein-D and cycloheximide on insulin and vanadate 
evoked changes in ETA and ETB mRNA expression 
Incubation of ASMC with the transcription inhibitor, actinomycin D (1.5 pg/ml), or 
the protein synthesis inhibitor, cycloheximide (10 pglml), per se for 20 hr did not 
evoke any appreciable changes in ETA and ETB mRNA levels. However, 
upregulation of ET receptor mRNA levels induced by insulin (Figure 32) and 
vanadate (Figure 33) was blocked by coincubation with either of these compounds, 
indicating the requirement of transcription and protein synthesis in the effects of 
insulin and vanadate on ETA and ETB mRNA expression. 
Figure 28. Time course of increases in ET receptor mRNA levels induced by 
insulin. Confluent ASMC were incubated with serumfree DMEM containing 100 
n M  insulin for the indicated time intervals (6,12, & 20 hr). Control ASMC (C) were 
incubated with serum-free DMEM alone for 20 hr. After the 20 hr incubation, total 
RNA was isolated, fractionated (20 pgnane) on 1% agarose formaldehyde gel, 
transferred to nylon membrane and hybridized with labeled ETA or ETB cDNA 
probe. The blots were rehybridized with labeled P-actin probe. The upper panel 
shows a representative blot of a single experiment, and the lower panel depicts the 
pooled mean * SEM values after densitometric analysis of three separate blots with 
data expressed as % change compared to control (100Y0) value. Control value for 20 
hr period is shown in the figure. 
** p < 0.01 vs. untreated control 

Figure 29. Time course of increases in ET receptor mRNA levels induced by 
vanadate. Upper panel is a blot fiom a representative experiment while the lower 
panel is a pooled mean i SEM value of densitometric analysis for each time point 
fiom 4 different blots. 
*p < 0.05; ** p < 0.01 vs. untreated control 
Figure 30. Effect of genistein on ET receptor mRNA changes evoked by insulin. 
The upper panel is representative of a single experiment while the lower panel shows 
mean SEM of 4 separate experiments. 
* * p < 0.01 vs. control group 
Figure 31. Effect of genistein on ET receptor mRNA changes evoked by vanadate. 
Upper panel is a representative experiment while the lower panel is pooled mean * 
SEM value of densitometric analysis from 4 different blots. 
* * p < 0.0 1 vs. control group 
Figure 32. Effect of actinomycin D and cycloheximide on insulin evoked increases 
in ET receptor mRNA in ASMC. Actinomycin D (AD; 1.5 p-1) or cycloheximide 
(CX; 10 pg/ml) was added during insulin incubation as indicated. Upper panel is a 
representative experiment while the lower panel is pooled mean * SEM value of  
densitometric analysis fiom 4 different blots. ** p < 0.0 1 vs. control group 
Figure 33. Effect of actinomycin D and cycloheximide on vanadate evoked changes 
in ET receptor mRNA. Upper panel is a representative experiment while the lower 
panel is pooled mean SEM value o f  densitometric tracing of 4 separate 
experiments. 
* * p < 0.01 vs. control group 
4.3. In vivo effects of insulin and vanadate in streptozotocin diabetic and non- 
diabetic rats 
4.3.1. Analysis of metabolic variables 
Body weight and food intake for all groups before and after the 2-week treatment 
period is shown in Tables 3 and 4. The body weights of diabetic rats before 
treatment (3-weeks post-STZ) were lower (p < 0.01) than in normal rats in all 
groups. Over the 2-week treatment period, untreated diabetic rats failed to show a 
significant increase in body weight. Diabetic rats treated with vanadate gained less 
weight than their untreated counterparts. These observations are in accordance with 
other studies showing that, under short-term treatment ( a 0  days) with vanadate, 
diabetic rats tend to lose weight (Becker et al. 1994). Insulin treated diabetic rats, on 
the other hand, gained weight over the treatment period. Food intake was 
significantly greater in all untreated diabetic rats than in all non-diabetic control 
groups. Both vanadate and insulin treatment significantly lowered food intake in 
diabetic rats to near the level of untreated non-diabetic controls. Vanadate treatment 
also reduced food intake in non-diabetic rats. Vanadate intake, calculated by 
multiplying water intake by vanadate concentration, amounted to 30 _+ 0.7 
mg/rat/day in diabetic rats, and 22 + 1.3 mg/rat/day in non-diabetic rats. This dose is 
in line with previous studies showing beneficial effects of vanadate on blood glucose 
concentrations (Brichard & Henquin, 1995; Becker et al. 1994). 
Blood glucose and plasma insulin concentrations for all groups are also shown in 
Tables 3 and 4. Both untreated diabetic groups had higher fasting plasma glucose 
and lower plasma insulin levels than their non-diabetic counterparts. Insulin and 
vanadate treatment dramatically lowered plasma glucose concentrations in the 
diabetic rats. As expected, insulin treatment raised plasma insulin levels in both 
diabetic and non-diabetic groups while vanadate treatment had no significant effect. 
Additionally, insulin treatment of diabetic rats raised plasma insulin levels above 
that of untreated, non-diabetic controls, but not above that of insulin treated non- 
diabetic controls. 
4.3.2. Analysis of ex vivo vascular reactivity in aortic rings 
Maximum evoked isometric tension (vasoconstriction) to ET- 1 was greater in aorta 
from both untreated groups of diabetic rats than in their non-diabetic counterparts. 
This relationship was present in aortic rings both with (Figure 34) and without 
(Figure 35) intact endothelium. Insulin and vanadate treatment restored ET-I 
evoked vasoconstriction in diabetic rats to control levels, but had no significant 
effect on ET-1 responses in non-diabetic rats. Once again, this relationship held true 
in both endothelium denuded and intact aortic rings. Also, there were no differences 
in ECso values amongst any of the groups with the exception of endotheliurn 
removal which shifted the cumulative concentration-response c w e  to ET-1 in all 
groups to the left with no change in Em, (Table 5). Similarly, methoxamine evoked 
vasoconstriction was greater in diabetic rats compared to non-diabetic controls and 
both insulin and vanadate treatment appeared to correct this abnormality (Figures 36 
& 37). Once again, these relationships held true in aortic rings both in the presence 
(Figure 36) and absence (Figure 37) of intact endothelium. Moreover, no 
differences in ECS0 values were observed amongst any of the groups with the 
exception of endothelium denuded groups exhibiting a shifi to the left in the 
cumulative concentration-response curves to methoxarnine with no significant 
differences in Em, values (Table 5). ACh evoked relaxations in methoxamine 
precontracted rings were unchanged in all groups (Figure 38). 
4.3.3. Analysis of plasma endotbelin-1 levels 
Plasma ET-1 concentrations as shown in Figure 40 were lower in untreated diabetic 
groups than in untreated non-diabetic groups (in pmol/L; untreated insulin group: 
SD, 1.04 + 0.20; STZ, 0.46 + 0.08, p < 0.05; untreated vanadate group: SD, 1.05 + 
0.18; STZ 0.39 + 0.06, p < 0.05). Plasma ET-1 concentrations were significantly 
higher in insulin and vanadate treated diabetic rats than in untreated animals (in 
pmoVL; insulin group: untreated, 0.46 _+ 0.08; treated, 1 .O9 + 0.19, p < 0.05; 
vanadate group: untreated, 0.39 + 0.06; treated, 0.88 _+ 0.1 2, p < 0.05). Non-diabetic 
rats treated with either vanadate or insulin also exhibited increased plasma ET-I 
concentrations compared with untreated groups (insulin group: untreated, 1.04 2 
0.20; treated, 1.94 2 0.1 2, p < 0.05; vanadate group: untreated, 1.05 + 0.1 8; treated, 
1.85 + 0.22, p < 0.05). 
TABLE 3 
Metabolic parameters in diabetic (STZ) and non-diabetic (SD) rats treated with insulin 
(12 rnU/Kg/min; s.c.) for 2 weeks. 
Group Body weight Body weight Food intake Blood glucose Plasma insulin 
before (g) after (g) (g-rat-l .day-') (mrnol/L) (pmoVL) 
STZ-insulin 285+14" 3 6 1 + 1 5 ~  33k1.5' 8.4 + 0.9' 1560 + 127' 
Data are mean * SEM from 8 separate rats 
p < 0.001 vs control-SD group 
< 0.0 1 vs respective untreated group 
' p c 0.001 vs respective untreated group 
TABLE 4 
Metabolic parameters in diabetic and non-diabetic rats treated with vanadate (0.5 mg/ml; 
p.0.) for 2 weeks. 
Group Body weight Body weight Food intake Blood glucose Plasma insulin 
before (g)  after (g) (g-mt-' -day-') (mrnoVL) (prnoYL) 
Data are mean k SEM fiom 8 separate rats 
a p < 0.001 vs. control-SD group 
p < 0.0 1 VS. respective untreated group 
' p < 0.00 1 vs. respective untreated group 
Log Molar ET- 1 
Figure 34. Cumulative-concentration response curves to ET-1 (100 pmol/L - 50 
nrnolk) in aortic rings with intact endothelium from 5-week ST2 diabetic rats and 
non-diabetic controls. Each group was either untreated or treated with insulin (a; 
s.c. 12 mU/Kg/min) or vanadate (b; p.0. 0.5 mg/ml) for 2-weeks. Each data point 
represents the mean f SEM of 8 determinations using tissues from 8 different rats. 
Log Molar Endothelin- 1 
Figure 35. Cumulative-concentration response curves to ET-1 (100 pmollL - 50  
nmolk) in aortic rings with denuded endothelium from diabetic (STZ) and non- 
diabetic (SD) control rats. Each group was either untreated or treated with insulin 
(a; S.C. 12 mUKg1min) or vanadate (b; p.o.0.5 mg/ml) for 2-weeks. Each data point 
represents the mean + SEM of 8 determinations using tissues from 8 different rats. 
Log Molar Methoxamine 
Figure 36. Cumulative-concentration response curves to methoxamine (100 n m o n  
- 100 pmoVL) in aortic rings with intact endothelium fiom diabetic (STZ) and non- 
diabetic (SD) control rats. Each group was either untreated or treated with insulin 
(a; S.C. 12 mU/Kg/min) or vanadate (b; p.o.O.5 mg/ml) for 2-weeks. Each data point 
represents the mean + SEM of 8 determinations using tissues fiom 8 different rats. 
Log Molar Methoxamine 
Figure 37. Cumulative-concentration response curves to methoxamine ( 100 nmol/L 
- 100 p o I / L )  in aortic rings with denuded endothelium from diabetic (STZ) and 
non-diabetic (SD) control rats. Each group was either untreated or treated with 
insulin (a; s.c. 12 mUn<glmin) or vanadate (b; p.0. 0.5 mg/ml) for 2-weeks. Each 
point represents mean f SEM of 8 determinations using tissues fkom 8 different rats. 
Figure 38. C umulat ive-concentration response curves to acetylcholine ( ACh) 
evoked relaxation (100 nmol/l - 100 pmol/l) in rat aortic ring preparations 
precontracted with methoxamine ( 1  00 p o l / l )  from diabetic (STZ) and non-diabetic 
(SD) control rats. Upper panel - (a) insulin group; lower panel - (b) vanadate group. 
Each point is mean + SEM of 8 determinations using tissues from 8 different rats. 
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Figure 39. Plasma ET- 1 levels in Sprague-Dawley (SD) control and streptozotocin 
(STZ) diabetic rats either treated with insulin or vanadate or untreated. Plasma ET- 1 
was measured with a RIA kit capable of distinguishing between ET and big-ET, but 
not between the different isoforms of ET. Results represent mean * SEM of 8 
separate determinations using plasma samples From 8 different rats. 
*p < 0.05 vs. respective non-diabetic control; and +p < 0.05 vs. respective diabetic 
control. 
5. DISCUSSION 
5.1. Insulin effects on ET receptor expression and action 
5.1.1. Summary 
Long-term (24 hr) pretreatment of rat ASMC with a high concentration of insulin 
enhances ET-1 evoked peak [Ca2+Ji responses. This is primarily due to enhanced 
ETA receptor signaling, as the ETA selective antagonist BQ123 significantly 
attenuated the enhanced [caz+li response to ET-1 to similar levels in both treated 
and untreated ASMC, whereas BQ788 (ETB selective anatagonist) attenuated the 
response to a lesser extent in both groups. The ETB selective agonist, IRL-1620, 
evoked a concentration dependent increase in peak [Ca2+Ji levels in both groups of 
ASMC, albeit to a much lower extent than to ET-1, and failed to eiicit greater 
responses in insdin pretreated ASMC. 
5.1.2. Mechanistic considerations 
While other subcellular mechanisms cannot be ruled out, it is probable that insulin 
evoked enhancement of ET-1 evoked [Ca2+Ii signaling is due to ETA (but not ETB) 
receptor upregulation since ETB-evoked [ca2+] responses remained unaltered. 'fhis 
is consistent with the observation that insulin pretreatment significantly and 
maximally upregulated only ETA binding sites in a concentration and time 
dependent manner. Also, insulin significantly increased ET- 1 evoked peak [Ca*+] 
responses at a concentration as low as 10 nM. This effect is selective to ET-1 since 
[Ca2+Ji responses to both AVP and Ang II remained unaffected. These data suggest 
that insulin selectively enhances ETA gene expression leaving VSMC AT1 and VI 
receptor expression unaltered. In fact, it has been previously shown that insulin 
pretreatment of rat mesenteric VSMC has no effect on [3H] AVP binding (Standley 
et al., 199 1 ). Moreover, the observation that IGF- I also selectively increased ET- 1 
evoked [ca*+li responses indicates that this effect of insulin might be mediated 
through the IGF-1 receptor, which is known to be activated by high insulin 
concentrations (King et al., 1980). 
The possibility that insulin could enhance ETA expression in ASMC was suggested 
earlier (Frank et al., 1993). It was demonstrated that incubation of either bovine 
ASMC, rat brain capillary pericytes or kidney afferent arterioles led to a two-fold 
increase in ET- 1 binding, increased [3H] thymidine incorporation (evidence in 
support of DNA synthesis and mitogenesis) and increased ETA mRNA levels. 
However, this study failed to characterize cell surface ETA and ETB binding sites in 
ASMC, the mechanism underlying changes in ETA expression, or the effect of 
insulin on [Ca*+Ii responses to ET agonists. Indeed, most of these smooth muscle 
cells are known to possess both ETA and ETB receptors. This thesis has addressed 
these issues and also demonstrates that exaggerated [Ca2+Ji responses evoked by 
long term insulin incubation are selective to ET-1 and not other vasoactive peptide 
agonists. The in v i m  data in this thesis with ASMC preincubated with high insulin 
were supported by direct saturation binding studies in hyperinsulinemic obese- 
Zucker rats fiorn our laboratory. These studies demonstrated that aortic rnicrosomal 
preparations fiom hyperinsulinemic Zucker rats contain a greater number of ETA 
specific binding sites than norrnoinsulinemic control lean rats (Hopfner et al., 
1998a). Soon after, another group demonstrated that vascular ETA receptor levels 
were also increased in hyperinsulinemic/insulin resistant fructose-hypertensive rats 
(Juan et al., 1998). These data support possible physiological relevance to our 
observations. 
Enhanced cell surface expression of ETA sites evoked by insulin is preceded by 
enhanced ETA mRNA expression, which becomes apparent after 12 hi= of insulin 
incubation. The increase in ETA mRNA was abolished by inclusion in the 
incubation medium of the transcription inhibitor, actinomycin D, and the protein 
synthesis inhibitor, cycloheximide, indicating the requirement for de novo protein 
synthesis in insulin mediated enhancement of ETA expression. The molecular 
mechanism by which insulin selectively promotes ETA expression is presently 
unknown, but the present observations suggest that it may be due to induction of a 
factor that can bind to one of several regulatory sequences on the ETA gene 
promoter. The signal transduction pathways recruited by insulin in the upregulation 
of ETA expression were not investigated; however, the blockade of ETA 
upregulation by genistein, a tyrosine kinase inhibitor, at both the receptor binding 
and mRNA expression levels indicates the requirement of tyrosine kinase activation. 
Insulin is known to activate several cytosolic proteins in eliciting its cellular 
response. Phosphatidylinositol-3-kinase (PI3K) has previously been shown to be 
important in insulin mediated enhancement of al-adrenoceptor expression in rat 
ASMC (Hu et al., 1996). Further work using intracellular enzyme inhibitors is 
needed to clarify this issue. 
5.1.3. Reconciliation with previous discrepant results 
Several studies provide evidence of a link between insulin and altered vascular 
reactivity. Insulin has been shown to attenuate agonist(s)-evoked [Ca2+Ii and/or 
contractile responses to agonists including ET-1 in different VSM preparations (Kim 
& Zemel, 1993; Dick & Sturek, 1996; Standley et al., 1991; Saito et al., 1993; 
Tirapattur et al., 1993; Touyz et al., 1994). This attenuation could be due to insulin 
evoked enhancement of Naf/K+ ATP'ase activity (Tirapattur et al., 1993), decreased 
influx of extracellular calcium in response to calcium mobilizing agonist stimulation 
via receptor or voltage gated calcium channels (Standley et al., 1991; Saito et al., 
1993), inhibition of [Ca*+Ii release (Standley et al., 1991), or to stimulation of 
sarcoplasmic ~ a * +  ATP'ases (Kim & Zemel, 1993). It is hypothesized that 
modulation of agonist evoked [CazcIi is a major mechanism by which insulin 
promotes vasodilatation, and in cases of insulin resistance, this effect may be lost 
promoting enhanced vasoconstriction (Sowers et al., 1993). The present study 
shows that longer term exposure to insulin actually increases ET-1 evoked [Ca2+li 
responses in isolated VSMC which may translate into enhanced contractile 
responses to ET-I in hyperinsulinemic states. The obvious discrepancy between 
these results and the aforementioned studies could be due to several factors. Firstly, 
previous studies showing that insulin attenuates agonist evoked [CazcJi responses 
were performed using insulin incubation of VSMC in vitro for a period not 
exceeding 120 min. The present study uses a 24 hr preincubation period after which 
agonist evoked [@+Ii responses were monitored. Northern blot analysis and 
receptor binding studies confirmed that this effect may be secondary to ETA receptor 
upregulation. It is possible therefore that any previous studies showing attenuated 
ET-I evoked [CazfIi responses with acute insulin incubation did not allow adequate 
time for enhanced ET~gene  expression to occur, hence the short term cellular 
response predominated. Indeed, the argument can be made that physiological 
hyperinsulinemia is more adequately mimicked with long term insulin 
preincubation. Secondly. unlike other acute studies, the present study did not include 
insulin in the medium when receptor binding, [Ca2+Ji or tension measurement 
studies were performed. However, it is unlikely that this would have a significant 
effect as upregulated ETA receptors would be present regardless of whether insulin 
is included in the cell suspension or not. Thirdly, desensitization to the short-term 
cellular effects of insulin on agonist evoked [Ca2+Ji changes may occur after a 
certain time period. Finally, in vivo data fiom our laboratory revealing that an 
increased number of ETA specific binding sites and exaggerated vasoconstrictor 
responses to ET-I exist in aorta fiom hyperinsulinernic obese Zucker rats support 
our in vitro observations that long-term exposure to higher than normal 
concentrations of insulin may in fact be associated with enhanced ET-1-evoked 
responses in in vivo hyperinsulinernic states (Hopfner et al., 1998a). 
5.1.4. Physiological Relevance 
Since the concentrations of insulin (10 - 100 nM) used in this study were ten to one- 
hundred fold higher than the physiological range, it could be argued that the present 
results may not reflect the situation in vivo in hyperinsulinemic states. However, it 
must be noted that it cannot be assumed that the physiologically effective 
concentration of any substance in cell culture medium will be the same 
concentration needed to evoke the same response in vivo. Indeed, our recent 
observation of increased ETA specific binding sites and increased vasoconstrictor 
responses to ET-1 in obese Zucker rats suggest that this phenomenon may occur in 
vivo as well in hyperinsulinemic states (Hopher et al., 1998a). It must be noted that 
the this obese rat model also exhibits altered plasma lipid profiles, hyperglycemia, 
insulin resistance, obesity and hypertension, factors all of which could contribute to 
the observed altered reactivity to ET- 1 (Kasiske et al., 1992). However, the in  vitro 
results from this thesis as well another recent in vivo study demonstrating enhanced 
ETA receptors in hyperinsulinemic fructose-hypertensive rats (Juan et al., 1 998) 
support the view that hyperinsulinernia could indeed contribute to increased ETA 
specific binding and exaggerated vascular responses to ET- 1 in vivo. 
5.1.5. Conclusion 
Incubation of ASMC for a minimum of 24 hr enhances ET-1 evoked peak [Ca*+Ii 
responses. This effect of insulin is mediated through a concentration and time 
dependent enhancement of ETA expression secondary to tyrosine kinase 
phosphorylation. High plasma ET-I levels have been characterized in diverse 
cardiovascular disorders that are often accompanied by hyperinsulinemia (Saito et 
al., 1990; Lerman et al., 1 99 1 ; Naruse et al., 1 99 1). Parallel increases in plasma ET- 
1 levels in concert with upregulated ETA receptor expression and Ca2+ signaling on 
the VSMC, as well as the comitogenic effects of insulin and ET-1 M e r  compound 
the potential for vasculopathy evoked by insulin induced enhancement of ET-1 
action at the VSM level. 
5.2. Vanadate effects on ETA and ETB receptor expression and action 
5.2.1. Summary 
In contrast to the selective effects of insulin on ETA expression, vanadate (25 pM) 
upregulates both ETA and ETB binding sites on ASMC. The effect of vanadate on 
ETB sites was more striking, as the ratio of ETA to ETB sites dropped from 7.3 in 
control ASMC to 1.8 in vanadate pretreated cells. In support of this observation, 
vanadate also increased both ETA and ETB mRNA levels, an effect that was 
dependent on both new protein synthesis and active transcription. This is the first 
report that provides evidence at the receptor and mRNA levels of a significant shift 
in ET receptor subtype expression in any cell population by vanadate pretreatment. 
In line with this data, the concentration- peak [Ca2+Ii responses to ET-1 (non- 
selective ETA/ ETB agonist) and IRL 1620 (selective ETB agonist) were 
significantly higher in vanadate pretreated ASMC, and the weak [Ca2+Ii responses to 
IRL 1620 observed in the control group of cells became prominent in vanadate 
pretreated cells. Moreover, control ET- 1 -evoked [Ca2+Ii responses could not be 
completely abolished by a high concentration of BQ123 (ETA selective antagonist), 
whereas BQ 788 (ETB selective antagonist) attenuated the response to a lesser 
extent. These data suggest the existence of a small ETB mediated response in 
addition to the predominant ETA response. However, in vanadate pretreated cells, 
the exaggerated [Ca2+Ji response attained with the same concentration of ET-1 was 
highly attenuated in the presence of either BQ123 or BQ788. These data confirm 
that vanadate induced ETA and ETB receptor upregulation is hctionally coupled to 
[Ca2+Ii mobilization in a manner predictive of the changes in cell surface expression 
of each receptor subtype. This is clearly in contrast to the observed effects of 
insulin, which appear to be selective to the ETA receptor. 
5.2.2. ETB receptor upregulation 
Earlier, based on receptor binding and functional studies it was proposed that ASMC 
possessed a single class of ET binding sites (Martin et al., 1991). Subsequently, 
using [l*SI] labeled ET-1, ET-2 and ET-3, it was shown that rat ASMC possess two 
classes of binding sites, an ET-1 and ET-2 preferring high affinity irreversible site 
(85%) and another site (15-20%) that binds all three isoforms with equal affmity in a 
reversible manner (Roubert et al., 1991). Based on our laboratories observation that 
sarafotoxin 6c, an ETB selective agonist, evoked much larger increases in [CazcIi in 
cultured ASMC derived from spontaneously hypertensive rats, it was suggested that 
there may be ETB sites on ASMC (Batra et al., 1993). Consistent with this notion, 
the presence of cell surface ETA and ETB specific binding sites (using competitive 
inhibition of [125~] ET-I radioligand) and ETA and ETe mRNA transcripts in tissue 
homogenates from human aorta and rat ASMC were established by others (Eguchi et 
al., 1994; Davenport et al., 1995; Winkles et al., 1993). In the present study, 
saturation binding data for the non-selective radioligand, ['251] ET-1, showed the 
best fit for a one site model since the KD values for Iigand interaction at both ETA 
and ETB were not significantly different. In contrast, [1251] IRL-1620 labeled only 
ETB sites; from this, could estimate the relative distribution of ETA (88%) and 
ETB (12%) sites by subtracting the value of total sites labeled by [I2511 ET-1. 
Although vanadate pretreatment led to significant increases in the number of ETA 
and ETB sites, its effect on the upregulation of ETB sites was much more 
pronounced. Again, this is contrast to insulin, which upregulated only ETA sites 
significantly. Interestingly, glycerol administration (at a dose of 10 mYKg that led to 
renal damage) increased the density of both ETA and ETB binding sites in the renal 
medulla of normal rats; in fact, renal ETB up-regulation induced by glycerol was 
much more pronounced than ETA (Roubert et al., 1994). A recent report has 
characterized the existence of a novel ETB receptor that shows similar high affinity 
characteristics for ETB selective ligands in membrane fractions of canine, monkey 
and human spleen (Narnbi et al., 1997). Data from the present study suggest that 
vascular ETB receptors present on rat ASMC also express such high affinity 
characteristics. 
5.23. Comparison with effects of insulin 
As mentioned earlier, in contrast to the well-established vasoconstrictor effect of 
vanadate (Bianchin et al., 1 993; DiSalvo et al., 1 993; Laniyonu et al., 1 994), insulin 
is a vasodilator under normal physiological conditions. However, several 
laboratories have now confirmed using both in vitro and in vivo models that insulin 
promotes the release of ET- 1, a powerful vasoconstrictor/mitogenic peptide (Oliver 
et al., 1990; Ferri et al., 1995; Wolpert et al., 1993). In addition, ET-1 levels have 
been shown to be higher in NIDDM, atherosclerosis and hypertension which are 
conditions often accompanied by hyperinsulinemia (Poch et al., 1 99 1 ; Takahashi et 
al., 1990; Haak et al., 1992). The observation that insulin selectively upregulates 
ETA binding sites and action in rat ASMC in vitro is in contrast to the effects of 
vanadate on both ETA and ETB receptors with a more pronounced effect on ETB. 
Vanadate's effects were also blocked by a very low concentration of genistein, a 
tyrosine kinase inhibitor, suggesting that protein tyrosine phosphorylation mediated 
events could contribute to its observed effects. It is accepted that vanadium 
compounds inhibit phosphotyrosine phosphatase, enhance tyrosine phosphorylation 
of the insulin receptor, and also act at sites distal to the insulin receptor (Brichard & 
Henquin, 1 995). Vanadate, via blockade of phosphotyrosine phosphatase, could 
promote the activation of insulin-independent (cytosoiic) tyrosine kinases, thus 
promoting events unrelated to insulin signaling which could account for the 
activation of the ETB receptor gene at the level of transcription. While it is doubfil 
that insulin signaling involves phosphorylation and stimulation of PLCy, vanadate 
activates this enzyme (Figure 9) and consequently enhances IP3 production, elevates 
[Ca2+Ii levels and activates PKC (Bianchin et al., 1993; Jonas & Henquin, 1996; 
Wenzel et al., 1995). Thus, vanadate evoked increases in ETB gene expression may 
involve insulin-independent but Ca2+ and/or PKC dependent mechanism(s). An 
interesting observation was that vanadate, in addition to enhancing ET-1 evoked 
[Ca2+] responses, dramatically attenuated Ang I1 evoked [Ca2+Ii responses. This 
effect was not observed with insulin or IGF-I. Further studies are required to 
determine the mechanism of this agonist-specific effect. 
5.2.4. Physiological Relevance 
The optimal concentration of vanadate (25 pM) used in this study closely 
corresponds to the blood level achieved in rodent studies assessing the antidiabetic 
efficacy of vanadate, which varied between 10 and 20 pM (Brichard & Henquin, 
1995). Increased ETs mRNA transcripts are present in late passage ASMC (Eguchi 
et al., 1994). This increase is accompanied by increased incorporation of cell 
surface ETB receptors as well as exaggerated IP3 formation and ASMC mitogenesis 
to an ETB selective agonist. It was suggested that such phenotypic alterations 
contribute to in vivo changes of increased ET-1 evoked VSMC proliferation and 
vascular remodeling encountered in conditions such as atherosclerosis and 
hypertension. Thus, alterations in ETB receptor expression and action may be 
present in different pathological states. As previously discussed, circulating as well 
as tissue ET-1 levels were found to be elevated in atherosclerosis and elevated 
preproET mRNA levels have been encountered in atherosclerotic human aorta (Poch 
et al., 1991; Winkles et al., 1993). Accordingly, ET-1 is recognized as one of the 
contributing factors to the development of atherosclerosis (Hasdai & Lerman, 1995). 
In the present study, the vanadate-evoked shift in ET receptor expression and 
increased Ca2+ signaling to ETB agonists seen in ASMC in early passages may 
mirror that seen in untreated ASMC maintained in late passages. Thus, it is possible 
that vanadate treatment could alter vascular responses to ET-I. 
5.2.5. Conclusion 
The present study demonstrates that pretreatment of rat ASMC with vanadate, an 
insulinomimetic agent, leads to increased ETA and ETB mRNA levels, increased cell 
surface ETA and ETB binding sites, and exaggerated peak [Ca2+Ii responses to both 
ET- 1 and the ETB selective agonist, IRL 1620. Strikingly, while only a 1.7 fold 
increase in ETA sites was detected, ETB sites were upregulated by an order of 7.8 
fold. This is in contrast to insulin, which only upregulated ETA sites significantly. 
In addition, ETB mediated signaling becomes markedly more pronounced 
after vanadate pretreatment, since IRL 1620-evoked very low Ca2+ signaling in the 
control group of ASMC but showed a concentration-dependent increase in [Ca*+Ji 
response in the vanadate pretreatment group. These changes in ASMC ET receptor 
expression could mimic those seen in altered vascular states. Although the 
medicinal value of vanadium and its benefit in nutrition, DM and metabolism of 
lipids has been advocated (Brichard & Henquin, 1995), the observation that lower 
concentrations of vanadate enhance ET receptor expression in ASMC warrants a 
closer evaluation of its vascular effects. 
53. In vivo effects in diabetic and non-diabetic rats 
5.3.1. Summary 
The physiological relevance of the aforementioned in vitro observations can be 
deduced fiom results in ST2 diabetic and SD non-diabetic rats treated with insulin 
and vanadate. Strikingly, it is apparent that the ST2 diabetic rat itself exhibits 
decreased plasma ET-1 levels and exaggerated ET-1 evoked vasoconstrictor 
responses. Administration of vanadate orally and continuous subcutaneous delivery 
of insulin for 2 weeks led to: 
a) a decrease in fasting plasma glucose to non-diabetic levels in ST2 rats, 
b) restoration of decreased plasma ET-I in ST2 diabetic rats to control levels, 
c) elevation of plasma ET-1 (-2-fold) in normal SD rats, and 
d) normalization of increased Em, to vasoconstrictor agonists in ST2 rats. 
Thus, the present study demonstrates, for the first time, that short term insulin and 
vanadate treatment elevates plasma ET-1 levels, and prevents or reverses the 
exaggerated vasoconstrictor responses to ET-1 encountered in STZ diabetic rats. 
Thus, while our in vitro observations might have indicated that vasoconstrictor 
responses to ET-I would be attenuated in hypoinsulinemic STZ rats and 
exaggerated in insulin and vanadate treated animals (due to the changes in levels of 
insulin), in fact, precisely the opposite was the case, in that exaggerated responses to 
ET-1 were present in STZ rats which were decreased to normal levels by insulin and 
vanadate treatment. 
53.2. Altered endothelin-1 plasma levels in diabetes 
The role of ET-I in the diabetic state is controversial. As previously discussed, 
hyperlipidemia, hyperglycemia, and hyperinsulinemia are all thought to alter plasma 
levels of ET-I in the diabetic state, but the direction of these changes is uncertain. 
In contrast to our observation of decreased plasma ET-1 levels in ST2 rats, some 
studies have shown increased plasma ET-1 in ST2 rats and IDDM patients (Haalc et 
al., 1 992; Tada et al., 1 994; Makino & Kamata, 1 998; Takahashi et al., 1 990; Takeda 
et d., 1991). On the other hand, in support of our observations, significantly lower 
plasma ET-1 levels in IDDM patients and undetectable ET- 1 immunoreactivity in 
plasma of ST2 rats has also been reported (Smulders et al., 1994; Malmitsi-Puchner 
et al., 1996; Takahashi et ai., 1991). Similarly, in vitro studies with cultured bovine 
or porcine aortic EC have shown both elevated and decreased levels of ET-1 
production by the addition of high glucose to the culture medium (Hattori et al., 
1991 ; Yamauchi et al., 1990). As previously discussed, the reasons for these 
discrepancies in vivo may be due to the degree and duration of hyperglycemia, 
presence of diabetic complications, and possibly to the state of endothelial function 
in the model studied. An interesting possibility is that differences in EDRF 
production might contribute to these variations since EDRF function declines in 
proportion to the duration of hyperglycemia in STZ DM, and EDRF is known to 
inhibit ET-1 release (Boulanger and Luscher, 1990; Chang & Stevens, 1992). 
Acetylcholine-evoked relaxation of aortic rings was intact in the present study, 
suggesting that EDRF production remained unaffected by ST2 DM in this VSM 
preparation. Thus, it may be that unaltered EDRF production along with diminished 
plasma insulin levels in the untreated ST2 group resulted in decreased ET-1 
production - since insulin stimulates ET-1 release fiom vascular EC (Oliver et al., 
1990). Longer-term ST2 rats exhibit augmented ET-1 levels secondary to 
endothelial dyshction and attenuated EDRF production (Hopfher et al., 1999a). 
5.3.3. Insulin and vanadate increase ET-1 plasma levels 
The observation that insulin treatmefit restores plasma ET-1 to normal in ST2 rats, 
and increases it 2-fold in normal control rats might be explained by either its direct 
actions on EC or by indirect effects on other metabolic variables. These include: 
a) normalization of hyperglycemia and hyperlipidemia resulting in normalization of 
ET production fiom EC, 
b) normalization of hyperglycemia leading to decreased glucose mediated EDRF 
production (Wascher et al., 1994) and consequently, decreased EDRF mediated 
inhibition of ET- 1 release (Boulanger and Luscher, 1990) andor 
c) the direct effect of insulin on endothelial ET- 1 production (Oliver et al., 1990). 
The observation that vanadate increases plasma ET-1 in a manner similar to insulin 
in both ST2 and normal rats is novel; however, as noted earlier, vanadate is well 
known to mimic most of the cellular and metabolic actions of insulin via inhibition 
of protein tyrosine phosphatases, leading to enhanced insulin sensitive and non- 
sensitive tyrosine kinase activation. Thus, vanadate may enhance plasma ET-1 in a 
manner similar to insulin. 
53.4. Vanadate effects on food-intake 
In the present study, vanadate treatment reduced food intake in both normal and 
diabetic rats. Earlier it has been shown that the hypophagic effect of vanadate is 
only transient (Decker et al., 1994). No studies to date have assessed the effect of 
hypophagia on plasma ET-1 in normal or diabetic states. Three points deserve 
mention here: 
a) vanadium compounds both in vivo and in vitro mimic most, if not all of the 
metabolic actions of insulin, 
b) both insulin and vanadate evoke similar effects on ET-1 action and, 
c) it is now well established that the effects of vanadate on metabolic parameters 
are separate fiom its effects on hypoghagia (Brichard & Henquin, 1 995). 
It is thus improbable that reduced food intake contributed to the alterations in plasma 
ET levels in this study. 
53.5. Alterations in ET-1 reactivity in diabetes 
While our study suggests that ST2 DM is associated with increases in 
vasoconstrictor responses to both ET-1 and methoxamine, other studies have shown 
both decreased (Fulton et al., 1991 ; Tada et al., 1994; Makino & Kamata, 1 W8), and 
increased (Kiff et al., 199 1 ; Tammesild et al., 1 992), vasoconstrictor and vasodilator 
responses to ET-1, and both decreased (Pfaffman et al., 1982; Cameron & Cotter, 
1992), and increased (White & Carrier, 1990; Chang & Stevens, 1992; Ozcelikay et 
al., 1994), responses to a,-adrenergic stimulation in ST2 rats. As noted before, this 
inter-study variation may be due to differences in vascular bed studied, the severity 
and duration of hyperglycemia, and differences in experimental procedures for 
measuring vasoconstriction (Tomlinson et al., 1 992). Some studies showing 
increased vasoconstrictor responses in ST2 diabetic rats to various agonists have 
demonstrated the increase to be of a non-specific nature leading to enhanced 
vasoconstriction regardless of the agonist used (White & Carrier, 1990; Chang & 
Stevens, 1992). Our observation that plasma ET-1 is decreased in ST2 rats suggests 
ET receptor upregulation as a potential mechanism whereby responses to ET-1 ex 
vivo would be enhanced. A recent study has demonstrated desensitized ETA 
mediated vasoconstrictor and ETB mediated vasodilator responses in the perfused 
mesenteric vascular bed along with elevated plasma ET-1 levels in 10 week STZ 
diabetic rats (Makino & Karnata, 1998). Their results suggest that elevated ET-1 
induced receptor down regulation may have contributed to desensitized vascular 
responses. In the present study, while we cannot rule out receptor changes due to 
attenuated ET-1 levels, it is probable that another common mechanism is responsible 
for elevated reactivity to ET-1. This is supported by the fact that both methoxarnine 
and ET-I evoked vasoconstrictor responses are enhanced (non-specific effect), both 
in the presence and absence of intact endothelium (endothelium independent). 
Alterations in metabolic parameters such as plasma lipids, glucose, and insulin levels 
could all potentially contribute to alterations in VSM function in ST2 DM 
(Tomlinson et al., 1992), leading to a generalized enhancement of the contractile 
state of the vasculature. Importantly, it is apparent that insulin deficiency, at least 
under the conditions in the STZ rat, does not lead to attenuated ET-1 evoked 
responses as might have been expected from the in vho results. 
53.6. Insulin and vanadate correction of endothelin-1 reactivity 
Insulin treatment has previously been shown to normalize altered contractile 
responses in the ST2 rat (Pfkfkan et al., 1982; Heygate et al., 1996). Furthermore, 
in addition to its well established insulinomimetic effects on metabolic abnormalities 
in the STZ rat (Bnchard & Henquin, 1995), at least one group has shown oral 
vanadate therapy to improve vascular reactivity in this model (Ozcelikay et al., 
1994). In this study, however, the effect of long-term (10-weeks) treatment was 
assessed and neither responses to ET-1 nor comparisons to insulin were undertaken. 
Given increasing evidence that metabolic abnormalities are a major causative factor 
in diabetic vascular complications - and the fact that they are reversible by insulin 
treatment and restoration of metabolic control, it is likely that the beneficial effects 
of these compounds are mediated by correction of metabolic parameters in the STZ 
rat (Tomlinson et al., 1992; Pfaffman et al., 1982; Heygate et al., 1996). 
Furthermore, since exaggerated responses are corrected in both endothelium 
denuded and intact aorta, it is likely that correction of abnormal vascular responses 
in the STZ rat occurs at the VSM level. 
5.3.7. Physiological Relevance 
As previously discussed, ET- 1 is a potent endothelial derived vasoconstrictor and 
mitogenic peptide. Its potency and long lasting effects suggest that it is an integral 
component in local control of blood flow. Altered ET-I action, and elevated plasma 
ET-1 levels have been observed in several cardiovascular disease states. Despite the 
fact that ET-I is known mainly as a paracrine hormone, plasma levels of ET-1 might 
parallel that released in a paracrine manner by the vascular endothelium (Lerman et 
al., 1991). The observation that ST2 DM leads to alterations in plasma ET-1 levels 
and VSM action implicates this peptide as  a contributor to the vascular 
complications observed in this animal model of IDDM. Moreover, normalization of 
these indices of ET-1 activity by insulin and vanadate treatment of provides m h e r  
evidence of beneficial vascular effects of these compounds. Specifically, changes in 
aortic reactivity to ET-I (as demonstrated in this study) might contribute to changes 
in systolic blood pressure or to changes in susceptibility to large vessel 
atherosclerotis in diabetes. 
5.3.8. Reconciliation of in vivo with in vitro results 
Our in vitro results have shown that insulin per se is able to upregulate ETA 
receptors, and vanadate to upregulate ETA and ETB receptors, in cultured ASMC. 
Furthermore, we have recently observed that aortic tissue from hyperinsulinemic / 
insulin resistant obese Zucker rats exhibit increased ETA receptor levels (Hopfner et 
al., 1998a). Thus, it is plausible that insulin has the capability to regulate not only 
ET-1 peptide expression, but also, at higher concentrations, regulate ET receptor 
expression in vivo. Thus, along with VSM mitogenic and other hypertension- 
promoting effects (Schemer & Sartori, 1997), high plasma insulin may promote 
adverse cardiovascular events via augmented ET-1 action at the VSM level. Indeed, 
the observation that vascular complications still arise in diabetic patients despite 
adequate glucose control lends credence to the concept that insulin treatment may 
promote adverse vascular complications (Kroc Collaborative Study Group, 1984). 
However, as demonstrated by the present study, poor metabolic control associated 
with hypoinsulinemia may also promote a general enhancement of vascular 
reactivity in addition to various other well-known adverse cardiovascular effects 
(Tomlinson et al., 1992). These observations underscore the importance of 
achieving tight metabolic control of IDDM (minimizing fluctuations between 
insulinemia and glycemia/lipidemia) in order to prevent potential ET- 1 mediated 
cardiovascular complications in this metabolic disorder. 
It is notable that a minimum concentration of 10 nM of insulin was required to 
upregulate ETA receptors in the in vitro arm of this study while under treatment 
conditions, ST2 and non-diabetic rats under insulin treatment never achieved greater 
than a 2 nM concentration of insulin in the plasma. Thus, it is plausible that the 
plasma concentration of insulin never reached the threshold level at which it would 
be capable of upregulating ETA receptors in vivo - explaining why induction of 
hyperinsulinemia with exogenous insulin supplementation did not promote 
exaggerated responses to ET-1 in vascular tissue ex vivo in the present study. On the 
other hand, one cannot assume that the concentration of an agonist required to 
induce an effect in vitro would be the same as that required to elicit similar effects in 
vivo. This is particularly relevant in the present study since the in vitro arm of this 
study simply used VSMC in culture, while the in vivo situation obviously would 
have been influenced by the vascular endothelium as well as interactions with other 
circulating factors. Moreover, while plasma vanadate concentrations were not 
measured in this study, the chosen dose was previously shown to result in plasma 
concentrations of - 20 pM, a concentration adequate to promote changes in ET 
receptor expression in vitro. Thus, drawing direct comparisons between the in vitro 
and in vivo effects of insulin and vanadate in this study is quite difficult. 
5.3.9. Conclusion 
The present results demonstrate that 5-week ST2 diabetic rats exhibit enhanced 
agonist-evoked vasoconstrictor responses and decreased plasma ET- 1 levels relative 
to non-diabetic controls. Both insulin and vanadate treatment of ST2 rats for 2 
weeks normalized these alterations. Since recent research has focused on metabolic 
abnormalities as a major causative factor in diabetic vascular complications (DCCT, 
1993; Kroc Collaborative Study Group, 1984), the beneficial effects of insulin and 
vanadate on metabolic control suggests a beneficial effect on adverse cardiovascular 
alterations in ST2 DM treated with these compounds. Despite potential atherogenic 
and hypertensiogenic effects, including upregulation of ET receptors at the VSM 
level, insulin and vanadate therapy in IDDM may beneticially affect alterations in 
vascular ET activity present in the ST2 diabetic rat (Figure 40). 
Figure 40. Summary of effects of diabetes, insulin, and vanadate on vascular ET 
activity. Factors associated with the diabetic state per se including hyperglycemia, 
hyperlipidemia, and endothelial dysfunction modulate both the release and responses 
to ET-1. Insulin and vanadate, while also having direct effects in promoting ET-1 
release and action, may actually correct abnormalities in ET-1 activity in the diabetic 
state through restoration metabolic control. 
6. SUMMARY & CONCLUSIONS 
6.1. Insulin upreplates ETA receptor expression and [Ca*+li responses in rat 
aortic smooth muscle cells 
While insulin is known to promote VSM relaxation, it also enhances ET-1 secretion 
and action in conditions such as NIDDM and hypertension. In an effort to elucidate 
the effect of insulin on responses to ET-I, this thesis first examined the effect of 
insdin pretreatment on [Ca2+Ji responses to ET-I in cultured ASMC. Pretreatment 
of rat ASMC with insulin (10 n M  for 24 hr) failed to affect basal [Ca*+Ii levels but 
led to a significant increase in peak [CazfJi responses (1.7 fold; p < 0.01) to ET-1. 
The responses to IRL-1620 (an ETB selective agonist), Ang I1 and AVP remained 
unaffected. Since IGF- 1 evoked similar effects, it was concluded that these effects 
of insulin might be mediated by stimulation of the IGF-1 receptor. ET-1-evoked 
peak [cazcli responses were significantly attenuated by the inclusion of the ETA 
antagonist, BQ 123. The ETB antagonist, BQ788, abolished [ca2+li responses to 
IRL-1620, but failed to S e c t  the exaggerated [ca2+li responses to ET- I. Saturation 
binding studies revealed a 2-fold increase (p < 0.01) in the maximal number of 
binding sites labeled by [I2511 ET-1 in insulin pretreated cells and no significant 
differences in sites labeled by [lZSI] IRL 1620 between control and treatment groups. 
Northern blot analysis revealed an increase in ETA mRNA levels after insulin 
pretreatment for 20 hr, an effect that was blocked by genistein, actinomycin D, and 
cycloheximide. Parallel studies in our laboratory revealed a two-fold higher number 
of @ < 0.01) ETA specific binding sites in aorta &om obese Zucker rats compared to 
lean controls (Hopher et al., 1998a), and another study has recently demonstrated 
similar results in hyperinsulinemic mtctose-hypertensive rats (Juan et al., 1998). 
These data suggest that insulin exaggerates ET- 1 evoked peak [cazcli responses via 
increased vascular ETA receptor expression. This may represent a potential 
mechanism whereby insulin contributes to enhanced vasoconstriction observed in 
hyperinsulinernic or insulin treated conditions. 
6.2. Vanadate upregulates ETA and ETB receptor expression and [Ca2+li 
responses in rat aortic smooth muscle cells 
The insulinomimetic agent, vanadate, has been considered recently for clinical use in 
the management of both IDDM and NIDDM. In parallel with insulin, the present 
study characterized the effect of vanadate pretreatment on changes in ET-1 binding, 
ETA and ETB mRNA expression, and ET-1 evoked [&+Ii levels in rat ASMC. 
Similar to insulin, preincubation with vanadate also induced a concentration and 
time-dependent increase in specific binding of [12SI] ET-1. Maximal increases were 
seen with 25 pM vanadate pretreatment for a period of 24 hr, and this effect was also 
abolished by the tyrosine kinase inhibitor, genistein. Vanadate also evoked an 
increase in the maximal number of specific binding sites for the non-selective [1251] 
ET-1 radioligand and, in contrast to insulin, for the ETe selective radioligand, [12SI] 
IRL 1 620 as well - with the latter being increased to a greater extent. In line with 
this binding data, vanadate also induced an increase in both ETA and ETB mRNA 
that was abolished by both cycloheximide and actinomycin-D. Similarly, increased 
receptor expression is coupled to enhanced ETA and ETB signaling, as vanadate 
pretreatment led to exaggerated peak [ca*+li responses to either ET-1 or IRL- 1620 
in a manner reflective of receptor expression characteristics. Thus, vanadate, unlike 
insulin which upregulates only ETA expression, upregulates both ETA and ETB 
receptor expression in rat ASMC. Despite beneficial insulinomimetic effects, 
vanadate may also influence diabetic vascular alterations via exaggerated VSMC 
responses to ET- 1. 
6.3. Insulin and vanadate normalize decreased plasma ET-1 and exaggerated 
vascular responses in the streptozotocin diabetic rat 
Since our in vitro results indicated a possible mechanism whereby insulin and 
vanadate might promote exaggerated vasoconstriction to ET-1 under treatment 
conditions, the last arm of the study examined the effects of oral vanadate treatment 
(0.5 mg/ml; p.0.) and insulin infusion (12 mu. kg:lmin:l s.c.) for 2-weeks on 
plasma ET-I and vascular responses to the peptide as well as the aladrenoceptor 
agonist, methoxamine, in aortic ring preparations from ST2 induced diabetic and 
non-diabetic rats. Plasma ET-1 was lower @ < 0.01) in diabetic rats compared to 
normal controls. Insulin and vanadate restored this abnormality to control levels (p 
< 0. 01) and significantly increased plasma ET-I in the control (p < 0.05) group. 
Surprisingly, higher maximal tension responses to ET-I (p < 0.01) as well as 
methoxamine (p < 0.05) were present in aorta from STZ rats per se in both 
endothelium intact and denuded aortic preparations compared to control group. This 
was counter to our hypothesis that hypoinsulinemia would be associated with 
selectively attenuated vasoconstrictor responses to ET-1 in STZ rats due to the lack 
of upregulatory influence of insulin on ETA receptors. In addition, rather than 
further increasing responses to ET-1 in vivo, as our in vitro data might have 
indicated, both insulin and vanadate treatment actually normalized (attenuated) these 
exaggerated responses. It is concluded the profound metabolic dysregulation of ST2 
DM is associated with attenuated plasma ET-1 levels and a non-specific increase in 
vascular reactivity to vasoconstrictor agonists. Insulin and vanadate treatment 
restores metabolic variables as well as diminished plasma ET-1 levels to control 
levels and actually attenuates exaggerated ET-1 (and other agonist) evoked VSM 
responses in diabetic rats. Thus, in addition to well-known beneficial metabolic 
effects, insulin and vanadate may actually beneficially affect cardiovascular 
regulation in the STZ diabetic rat via normalization of abnormal ET-1 activity. 
7. FUTURE DlRECTIONS 
An examination of the cellular mechanisms through which insulin and vanadate 
increase ET receptor expression assumes importance. Earlier evidence indicates 
that insulin increases al-adrenergic receptor expression through a PI-3K linked 
pathway. Further studies with enzyme inhibitors would clarify this issue. 
Moreover, since vanadate primarily mediates its insulinomimetic effects through 
phosphotyrosine phosphatase inhibition leading to activation of both insulin 
sensitive (receptor tyrosine kinase) and insulin insensitive (cytosolic tyrosine 
kinase) pathways, it is likely that pathways linked to the latter are responsible for 
ETB receptor upregulation. Earlier evidence indicates that vanadate activates 
PLCy leading to increases in [Ca*+Il and activation of PKC. Such pathways may 
be linked to ETB upregulation. 
Since ET- 1 is thought to be primarily a paracrine hormone, determinations of 
tissue ET-1 peptide as well as ET receptor peptide and mRNA expression in 
untreated and treated type I and type I1 diabetic rats assume importance. One of 
the most important observations of this thesis is the profound dysregulation of 
ET-1 plasma levels and vascular responses in the diabetic state, and its 
normalization by restoration of metabolic control. Vascular tissue level 
measurements of ET-I and ET receptor levels would determine the full extent of 
these alterations and add more physiologically meaningful data to these 
observations. 
Determination of the factors responsible for changes in ET- 1 release and action 
in diabetic states. While ail of hyperglycemia, insulinemia, lipoproteinemia, and 
endothelial dysfbction have been shown to alter ET-1 release and action, 
determining the relative contribution of each assumes importance. Many of the 
treatment options in existence for use in DM differentially alter these variables 
and targeting those treatments that promote changes in ET regulation might be of 
additional cardiovascular benefit. 
Finally, and most importantly, determining the role of alterations in ET- 1 release 
and action in DM and under treatment conditions assumes importance. The role 
of ET-1 in DM is still controversial due to disparate results between different 
laboratories and a lack of definite proof that ET-1 causes diabetic vascular 
complications. If alterations in ET-1 activity in vivo indeed contribute to the 
cardiovascular complications of DM, then ET antagonists should have beneficial 
effects in alleviating some or all of these abnormalities. Thus, it assumes 
paramount importance that studies with ET antagonists in different models of 
DM be pursued to further examine this issue. 
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